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 “One never notices what has been done, one can only 
see what remains to be done” 
 
Maria Sklodowska-Curie (1867-1934)  
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Abstract 
 
Alcohol dehydrogenases are of high interest for the stereoselective synthesis of 
building blocks with multi-chiral centres. They are implemented for single 
enzymatic reduction or oxidation steps or be part of synthetic enzymatic multi-step 
cascades for the production of industrially relevant chiral synthons. 
Although biotransformations with alcohol dehydrogenases are widespread, 
enzymes, which accept sterically demanding substrates, especially α-hydroxy 
ketones, are not common in nature. Therefore chemical methods for the synthesis 
of chiral 1,2-diols are still first choice. 
As a drawback, alcohol dehydrogenases require expensive nicotinamide cofactors 
such as NAD(H) or NADP(H) for their activity. Prices of these cofactors prevent 
their application in stoichiometric amounts and therefore regeneration of 
nicotinamide cofactors is an essential issue for biotechnological purposes. Therefore 
a co-substrate is required that is transformed to the respective co-product in 
equimolar amounts relative to the product. This co-product has to be separated 
from the product or must be removed in situ, which decreases atom- and process 
economy. 
In this work the carboligation of two inexpensive aldehydes catalysed by ThDP-
dependent enzymes is combined with a subsequent reduction of the intermediately 
formed α-hydroxy ketone by alcohol dehydrogenases. Therefore, a suitable cofactor 
regeneration system with smart in situ co-product removal had to be developed in 
order to gain high eco-efficiency of the synthetic enzyme cascade. To achieve the 
aim, the following work packages were addressed: 
1. Investigation of the substrate range of eight available alcohol 
dehydrogenases with focus on reduction of bulky-bulky α-hydroxy ketones; 
2. Determination of the stereoselectivity of the first and the second step of the 
synthetic cascade; 
3. Selection of the most promising enzyme(s) for the reduction of α-hydroxy 
ketones (which turned out to be the alcohol dehydrogenase from Ralstonia 
sp.) and its detailed biochemical characterisation with focus on the reduction 
of α-hydroxy ketones; 
4. Evaluation of a suitable cofactor regeneration system (substrate-coupled and 
enzyme-coupled approach) for the enzymatic 2-step synthesis, where smart 
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implementation of co-substrates (benzyl alcohol or ethanol) allows in situ 
removal of the co-product (benzaldehyde or acetaldehyde) from the second 
cascade step by reusing it in the first catalytic step (carboligation) of the 
cascade; 
5. Reaction engineering of the synthetic multi-enzymatic cascade with 
assistance of mathematical modelling, to optimise the overall yield of the 
synthetic cascade. 
During this work two synthetic recycling cascade reactions using a substrate-
coupled and an enzyme-coupled approach for cofactor regeneration were developed. 
For the substrate-coupled approach benzyl alcohol was used as co-substrate, and 
the co-product benzaldehyde was reused as a substrate in the carboligation step. For 
the enzyme-coupled approach ethanol was chosen as a co-substrate and the 
resulting acetaldehyde was also reused as substrate for the C–C bond formation. 
Whereas good conversions (> 70%), but moderate stereoselectivities (dr syn/anti 
9:1) were obtained for the production of (1R,2R)-1-phenylpropane-1,2-diol in 
cascade reactions using the substrate-coupled approach, the enzyme-coupled 
approach yielded excellent conversions (> 95%) and diastereoselectivities 
(de > 99%). 
Furthermore, during this thesis the most promising alcohol dehydrogenase from 
Ralstonia sp. for the reduction of α-hydroxy ketones was subject of crystallisation 
studies for X-ray structural investigations in order to explain its high potential for 
conversion of especially bulky substrates. 
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Kurzfassung 
 
Alkoholdehydrogenasen sind für die stereoselektive Synthese von Molekülen mit 
mehreren chiralen Zentren von großer Bedeutung. Sie können entweder für 
einzelne enzymatische Reduktions- bzw. Oxidationsschritte oder als Teil von 
synthetischen enzymatischen mehrstufigen Kaskaden für die Produktion von 
industriell relevanten chiralen Synthesebausteinen verwendet werden. 
Obwohl Biotransformationen mit Alkoholdehydrogenasen weit verbreitet sind, sind 
Enzyme, die sterisch anspruchsvolle Substrate, insbesondere α-Hydroxyketone, 
akzeptieren, in der Natur selten. Daher sind chemische Verfahren für die Synthese 
von chiralen 1,2-Diolen bisher die erste Wahl. 
Ein Nachteil der Verwendung von Alkoholdehydrogenasen sind teure Nicotin-
amidcofaktoren wie NAD(H) oder NADP(H), die für die Katalyse benötigt werden. 
Die hohen Preise dieser Cofaktoren verhindern ihren Einsatz in stöchiometrischen 
Mengen. Aus diesem Grund ist die Regeneration von Nicotinamidcofaktoren ein 
wichtiges Thema für biotechnologische Anwendungen. Dazu wird ein Cosubstrat 
verwendet, das während der enzymatischen Cofaktorregenerierung in äquimolaren 
Mengen, relativ zum Produkt; zum entsprechenden Coprodukts umgesetzt wird. 
Dieses Coprodukt muss vom Produkt abgetrennt oder in situ entfernt werden. Dies 
verringert sowohl die Atomökonomie als auch die Wirtschaftlichkeit des Prozesses. 
In dieser Arbeit wird die Carboligation von zwei kostengünstigen Aldehyden durch 
Thiamindiphosphat-abhängige Enzyme katalysiert und mit einer anschließenden 
Reduktion des intermediär gebildeten α-Hydroxyketons zum 1,2-Diol durch 
Alkoholdehydrogenasen kombiniert. Dafür musste eine geeignete Cofaktor-
regenerierung mit in situ Coproduktentfernung entwickelt werden, um eine hohe 
Ökoeffizienz der synthetischen Enzymkaskade sicherzustellen. Um dieses Ziel zu 
erreichen, wurden folgende Arbeitspakete behandelt: 
1. Untersuchung des Substratspektrums von acht verfügbaren Alkohol-
dehydrogenasen mit Fokus auf die Reduzierung sterisch anspruchsvoller  
α-Hydroxyketone; 
2. Bestimmung der Stereoselektivität der ersten und der zweiten Stufe der 
synthetischen Kaskade; 
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3. Auswahl des vielversprechendsten Enzyms für die Reduktion von  
α-Hydroxyketonen (hier die Alkoholdehydrogenase aus Ralstonia sp.) und 
seine detaillierte biochemische Charakterisierung mit Fokus auf die 
Reduktion von α-Hydroxyketonen; 
4. Evaluierung eines geeigneten Cofaktorregenerationssystems (Substrat-
gekoppelter und Enzym-gekoppelter Ansatz) zur enzymatischen 2-Schritt-
Synthese, wobei die intelligente Wahl der Cosubstrate (Benzylalkohol bzw. 
Ethanol) eine in situ-Entfernung der gebildeten Coprodukte (Benzaldehyd 
bzw. Ethanol) des zweiten Kaskadenschritts durch dessen Wieder-
verwendung in der ersten katalytischen Stufe der Kaskade (Carboligation) 
ermöglicht; 
5. Reaktionstechnische Optimierung der synthetischen multi-enzymatischen 
Kaskade mit Hilfe mathematischer Modellierung zur Optimierung der 
Ausbeute der gesamten Kaskade. 
Während dieser Arbeit wurden zwei synthetische Recycling-Kaskadenreaktionen 
mit einem Substrat-gekoppelten und einem Enzym-gekoppelten Ansatz für die 
Cofaktorregenerierung entwickelt. Für den Substrat-gekoppelten Ansatz wurde 
Benzylalkohol als Cosubstrat verwendet und das entstehende Nebenprodukt 
Benzaldehyd als Substrat in dem Carboligationsschritt wiederverwendet. Bei dem 
Enzym-gekoppelten Ansatz mit Ethanol als Cosubstrat wurde das resultierende 
Acetaldehyd ebenfalls als Substrat für die C-C-Verknüpfung wiederverwendet. 
Während gute Umsätze (> 70%), jedoch begleitet von mäßiger Stereoselektivität  
(dr syn/anti 9:1), für die Herstellung des (1R,2R)-1-Phenylpropan-1,2-diols in der 
Kaskadenreaktionen unter Verwendung der Substrat-gekoppelten Ansatzes erzielt 
wurden, ergab der Enzym-gekoppelte Ansatz ausgezeichnete Umsätze (> 95%) und 
Diastereoselektivität (de > 99%). 
Des Weiteren wurden während dieser Arbeit für die, bezüglich der Reduktion von 
α-Hydroxyketonen, vielversprechendste Alkoholdehydrogenase aus Ralstonia sp. 
Kristallisationsstudien für die Röntgenstrukturanalyse durchgeführt, um das hohe 
Potenzial zur Umwandlung von insbesondere sterisch anspruchsvollen Substraten 
zu erklären  
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Ni-NTA nitrilotriacetic acid chelated with Ni2+ ions 
PAC  phenylacetylcarbinol, 1-hydroxy-1-phenylpropan-1-one 
PCR  polymerase chain reaction 
PEG  polyethylene glycol 
PDC  pyruvate decarboxylase 
PQQ  pyrroloquinoline quinone 
rac  racemic 
RADH alcohol dehydrogenase from Ralstonia sp.  
REV  reverse primer 
SADH alcohol dehydrogenase from Sphingobium yanoikuyae 
SDR  short-chain dehydrogenase/reductase 
SEC  size exclusion chromatography 
strep-  streptavidin tag 
TADH alcohol dehydrogenase from Thermus sp. ATN1 
TBADH alcohol dehydrogenase from Thermoanaerobacter brockii 
TEA  triethanolamine, tris-(2-hydroxyethyl)amine 
ThDP  thiamine diphosphate 
THF  tetrahydrofuran 
TR1  transition state 1 
TR2  transition state 2 
TRIS  2-amino-2-hydroxymethylpropane-1,3-diol 
UV  ultraviolet  
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1.1 Concept of Green Chemistry  
In order to maintain wealth, health and social justice alternative ways for the 
production of goods and energy supply need to be established to replace fossil fuel 
based feed stocks. Industrial (white) biotechnology is a key element and cutting-
edge technology for the vision of a bio-based economy. Strongly connected to the 
policy of bio-based economy is the concept of Green Chemistry, which is defined as 
“design of chemical products and processes to reduce or eliminate the use and 
generation of hazardous substances” (Anastas and Warner 1998; Anastas and 
Williamson 1996; Horvath and Anastas 2007).  
The concept of Green Chemistry consists of 12 principles, which were originally 
published in 1998 by Paul Anastas and John Warner, agents of the United States 
Environmental Protection Agency (EPA). These rules give a kind of roadmap for 
chemists how to implement green chemistry in chemical processes (Anastas and 
Warner 1998; Anastas and Williamson 1996; Horvath and Anastas 2007). They 
include: 
• PREVENTION – prevention of waste production instead of remediation; 
• HIGH ATOM ECONOMY – design of synthetic methods to maximise 
incorporation of all used materials in the overall process; 
• LESS HAZARDOUS CHEMICAL SYNTHESES – design of synthetic methods to 
minimise toxicity to human health and the environment; 
• SAFER CHEMICALS – design of chemical products to affect their desired 
function and simultaneously minimise their toxicity; 
• SAFER SOLVENTS AND AUXILIARIES – if possible, minimisation of the use of 
auxiliaries substances; if impossible – auxiliaries should be made benign; 
• HIGH ENERGY EFFICIENCY – reduction of energy requirements of the 
overall process; if possible, mild conditions (ambient temperature and 
pressure) should be used; 
• RENEWABLE FEEDSTOCKS – renewable raw materials or feedstock should 
be applied whenever it is practicable; 
• REDUCED DERIVATISATION – reduction of unnecessary derivatisation steps, 
which can produce additional waste; 
• CATALYSIS – catalytic amounts are favoured over stoichiometric reagents; 
• DEGRADABLE COMPOUNDS – design of chemical products that break down 
into innocuous products and do not persist in the environment; 
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• REAL-TIME ANALYSIS FOR POLLUTION PREVENTION – development of 
analytical methodologies for real-time, in-process monitoring and control 
prior to formation of hazardous substances; 
• INHERENTLY SAFER CHEMISTRY FOR ACCIDENT PREVENTION – selection of 
substances and their formulation used in a chemical process in order to 
minimise the potential for chemical accidents, including releases, 
explosions and fires. 
Recently, a modified generalisation of the 12 rules of Green Chemistry was 
summarised in one word, the acronym PRODUCTIVELY (Tang et al. 2005) (see 
below).  
P – prevent waste 
R – renewable materials 
O – omit derivatisation steps 
D – degradable chemical products 
U – use of safe synthetic methods 
C – catalytic reagents 
T – temperature, pressure ambient 
I – in-process monitoring 
V – very few auxiliary substrates 
E – E-factor, maximise feed in product 
L – low toxicity of chemical products 
Y – yes, it is safe 
In the new PRODUCTIVELY concept the order of some rules was changed and 
some of the principles were combined in one point. The simplified approach allows 
rapid understanding of the idea of Green Chemistry.  
 
1.2  Industrial biotechnology  
All known biotechnological processes depend on enzymes – either in resting or 
living whole-cell systems or isolated biocatalysts (Höfer et al. 2009). These 
biological systems are implemented in the industrial biotechnology (also known in 
Europe as white biotechnology) for the manufacture of valuable products, 
improvement of industrial chemical processes, production of alternative energy (or 
“bioenergy”) and biomaterials. Furthermore, biotechnological processes are 
commonly used for the production of enzymes for textile, cosmetics, 
pharmaceuticals and for food-, pulp- and paper industry (Kirk et al. 2002; Kjellin 
and Johansson 2010; Sabale and Rane 2012; Torres et al. 2012; Vellard 2003). In 
2012 in Germany 10.5% of all biotechnological companies were classified with 
focus on industrial (white) biotechnology (Figure 1) (Ding et al. 2012). 
Biocatalysis, in which natural/biological catalysts are employed for the synthesis of 
organic compounds, is a key technology according to the Green Chemistry principles 
(see paragraph 1.1). Biocatalysis opens access to sustainable processes via 
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production of highly valuable products (e.g. chemicals, materials and fuels) from 
renewable resources by simultaneous reduction of energy consumption and waste 
production. 
 
Figure 1. Main activities of German biotechnology companies (only one classification per company) 
(Ding et al. 2012). 
Impressively, with biocatalysis almost every kind of chemical reaction seems to be 
accessible (Faber 2011). As mentioned above biocatalytical reactions can be 
conducted by isolated enzymes or with whole-cells. Both approaches have their 
advantages and disadvantages (Table 1). The major advantage of isolated cells is a 
lack of side reactions, which frequently occurs in whole-cell catalysis. On the other 
side, whole-cell biocatalysis does not require additional cofactor regeneration 
systems that have to be developed for every single reaction catalysed with isolated 
enzymes. Depending on the requirements of the final product, isolated enzymes as 
well as whole-cells find broad industrial applications, but (partially) purified 
enzymes are predominantly implemented. Processes with isolated enzymes are 
established for food and textiles processing, and they are also used as supplements 
for the production of feed and detergents, whereas whole cell systems are generally 
employed in the field of special chemicals providing a broad range of methods and 
processes (Bommarius and Riebel 2004; Höfer et al. 2009). 
In spite of the broad possibilities of enzyme-catalysed processes, biocatalysis and 
biotransformations are still often only the second choice in fine chemical industry 
(Meyer et al. 2013). This is caused by various factors; among them are e.g. substrate 
load limitations (e.g. poor substrate solubilities in aqueous systems) and sometimes 
low conversions (Table 2). Only if the requirements mentioned in Table 2 are 
fulfilled or no alternative chemical processes are available, biocatalysis is 
implemented nowadays. But the number of processes is continuously increasing 
(Meyer et al. 2013). 
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Table 1. Advantages and disadvantages of isolated enzymes and whole cells as biocatalysts  
(Faber 2011). 
Biocatalyst Form Advantages Disadvantages 
Isolated  
enzymes 
Any Simple apparatus, simple 
workup, better productivity due 
to a higher concentration 
tolerance 
Cofactor recycling necessary, 
limited enzyme stabilities 
 Dissolved  
in water 
High enzyme activities Side reaction possible, low 
solubility of hydrophobic 
compounds, workup requires 
extraction 
 Suspended  
in organic  
solvents 
Easy to perform, easy workup, 
hydrophobic compounds are 
soluble, easy enzyme recovery  
Reduced activities and 
stabilities 
 Immobilised Easy enzyme recovery  Loss of activity during 
immobilisation 
Whole cells Any No additional cofactor recycling 
system necessary, no enzyme 
purification required 
Expensive equipment, tedious 
workup due to large volumes, 
low productivity due to lower 
concentration tolerance, side 
reactions likely due to 
uncontrolled metabolism 
 Growing 
culture 
Higher activities Large biomass, enhanced 
metabolism, more by-products, 
process control difficult 
 Resting cells Workup easier, reduced 
metabolism, fewer by-products 
Lower activities 
 Immobilised 
cells 
Cell reuse possible Lower activities 
 
Table 2. Requirements for biotransformations in large scale (Hollmann et al. 2011;  
Huisman et al. 2010). 
Parameter Value 
Substrate concentration > 100 g L–1 
Conversion > 95% in 24 h 
Stereoselectivity > 99.5% ee 
Substrate-to-enzyme ratio > 50 (kg kg–1) 
Cofactor concentration < 0.5 g L–1 (< 0.5 mM) 
 
1.3  Enzymes in biocatalysis 
The application of biocatalysts can have many advantages, where homogeneous 
and heterogeneous catalysis in organic chemistry fails. Among them are the 
following features: 
• ENZYMES ARE OFTEN VERY EFFICIENT AND RAPID. Enzymes catalyse 
reactions up to 108-1010-fold faster in comparison to non-catalysed reactions 
(Menger 1993; Wolfenden 2011; Wolfenden and Snider 2001; Zechel and 
Withers 2000). As an outcome, chemical reactions require 0.5-1 mol% of 
catalysts, whereas most of enzymatic reactions are conducted with  
10–3-10–4 mol% (500-10 000-fold less) (Faber 2011). 
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• ENZYMES ARE ENVIRONMENTALLY FRIENDLY. In contrast to chemical 
catalysts (e.g. heavy metals or hazardous and toxic catalysts), enzymes are 
eco-friendly, since they are biodegradable. 
• ENZYMES WORK UNDER MILD CONDITIONS. The largest number of enzymes 
works under mild conditions regarding pH-value (between pH 5-8) and 
temperature (20-40 °C). There are some exceptions, where enzymes are 
working under unconventional conditions (extremely high/low 
temperatures and pHs), which are typical for enzymes isolated from 
extremophile microorganisms. For instance, for an alcohol dehydrogenase 
from Flavobacterium frigidimaris the temperature optimum was determined to 
be 70 °C, moreover the enzyme is stable at high temperatures (half-life: 
50 minutes, 60°C) (Kazuoka et al. 2007). Other examples are glucoamylases 
isolated from Pirophilus oshimae, Pirophilus torridus and Thermoplasma 
acidophilum. These enzymes are able to catalyse reactions under harsh 
conditions like a pH-optimum of 2 and a temperature optimum of 90 °C 
(half-life: 20 hours, 90 °C for Pirophilus oshimae and 24 hours, 90 °C for 
Pirophilus torridus and Thermoplasma acidophilum) (Serour and Antranikian 
2002). Enzymatic reactions under mild conditions minimise difficulties with 
isomerisation, epimerisation, racemisation, rearrangement, decomposition, 
protection/deprotection steps and other unwanted side reactions which are 
very common in chemical reactions (Lin et al. 2011). 
• ENZYMES CAN BE COMBINED, E.G. IN CASCADES. Since most of enzymes are 
capable to catalyse reactions under mild conditions, which for a number of 
enzymes are similar, there is a possibility of combining several catalytic steps 
in one reaction vessel yielding valuable product. In addition, enzymes have 
been successfully combined with chemical reactions for the production of 
important chiral synthons (Borchert et al. 2012; Gauchot et al. 2010, Husain 
et al. 2011). 
• ENZYMES ARE NOT LIMITED TO THEIR NATURAL REACTION. A number of 
enzymes are known to accept a broad substrate range, which is not limited 
only to its known natural set of substrates. Further, some enzymes catalyse 
more than one type of reaction. These combined features are defined as 
enzyme promiscuity. Enzyme promiscuity can be classified into: 
o CONDITION PROMISCUITY – where the enzyme is able to catalyse 
reactions under various conditions which are different from 
natural conditions, e.g. anhydrous media, higher temperatures or 
pHs; 
o SUBSTRATE PROMISCUITY – where enzymes show a broader 
substrate range compared to the physiologically predominantly 
converted substrate in the natural organisms; 
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o CATALYTIC PROMISCUITY – where enzymes clearly show 
different transition states during the reaction cycle. Here two 
different catalytic promiscuities can be distinguished: 
– ACCIDENTAL – where a side reaction is catalysed by the 
wild-enzyme; 
– INDUCED – a new reaction is established by one or several 
mutations rerouting the reaction catalysed of the wild-
enzyme (Hult and Berglund 2007). 
Aforementioned advantages of enzymes are very important, but one of the most 
crucial features of enzymes is that they catalyse chemical reactions highly 
stereoselectively. Three types of selectivity can be distinguished: 
• CHEMOSELECTIVITY – defined as “which functional group will react”. In 
detail: a reaction is performed by acting specifically on only one functional 
group in the presence of others. In chemistry usual functional groups that 
should not be transformed, have to be protected; 
• REGIOSELECTIVITY – defined as “where functional group will react”. 
Enzymes are able to distinguish differences between functional groups, 
which are identical but located in various positions; 
• STEREOSELECTIVITY – means “which stereoisomer reacts or from which site 
a prochiral compound is attacked”. In detail: a reaction is catalysed 
stereoselectively, when one stereoisomer is preferentially formed. 
 
1.4 Classification of enzymes 
Enzymes are classified by the Enzyme Commission that categorised all enzymes into 
six main groups depending on the reaction they catalyse (Table 3).  
Each enzyme in the classification has its own number, represented as follows: 
EC A.B.C.D. 
where:  
A – class of enzyme (one of the six enzyme classes of Table 3)  
B – enzyme subclass (e.g. for oxidoreductases, it displays the type of electron donors 
which are oxidised) 
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C – enzyme sub-subclass (e.g. for oxidoreductases, it displays for each type of electron 
donor the type of electron acceptor involved) 
D – enzyme sub-sub-subclass (running number, which is sometimes required to 
characterise new subdivisions in a sub-subclass). 
Table 3. Enzyme classification according to the Enzyme Commission (EC). 
EC 
number 
Enzyme class Catalysed reaction 
1 Oxidoreductases Oxidation/reduction reactions, e.g. oxidoreductases 
2 Transferases Transfer of functional group from one molecule to another, e.g. 
transaminases 
3 Hydrolases Hydrolysis of various bonds, e.g. lipases  
4 Lyases Synthesis or cleavage of covalent bonds (without ATP consumption), 
e.g. decarboxylases 
5 Isomerases Isomerisation within a single molecule, e.g. isomerases 
6 Ligases Connection of two molecules by consumption of ATP, e.g. 
synthetases 
Currently, all enzyme classes, despite the ligases, are industrially applied in the 
pharma-, food industry-, agrochemicals-, cosmetics- and polymer- sector and others. 
According to their application enzymes distribute as follows (Meyer et al. 2013) 
(Figure 1): 
 
Figure 2. Distribution of enzyme classes in industrial applications for the production of blockbusters 
(small molecule pharmaceuticals) (Meyer et al. 2013). 
According to the Figure 1 oxidoreductases (EC 1, 50%) and hydrolases (EC 3, 35%) 
are the most frequently used enzyme classes for the production of fine chemicals 
(Meyer et al. 2013). 
 
1.5  Oxidoreductases classification 
Oxidoreductases can be divided in 23 subgroups depending on the catalysed 
reaction (Boyce and Tipton 2005) (Table 4). 
Of highest interest in applied biocatalysis are oxidoreductases from the subgroups 
of dehydrogenases (EC 1.1) and oxygenases (EC 1.13 and EC 1.14).   
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Table 4. Classification of oxidoreductases according to their catalysed reaction (Boyce and  
Tipton 2005).  
No. Enzyme 
subclass 
Catalysed reaction 
1 EC 1.1 Acting on the CH–OH group of donors 
2 EC 1.2 Acting on the aldehyde or oxo group of donors 
3 EC 1.3 Acting on the CH–CH group of donors 
4 EC 1.4 Acting on the CH–NH2 group of donors 
5 EC 1.5 Acting on the CH–NH group of donors 
6 EC 1.6 Acting on NADH or NADPH 
7 EC 1.7 Acting on other nitrogenous compounds as donors 
8 EC 1.8 Acting on sulfur group of donors 
9 EC 1.9 Acting on a heme group of donors 
10 EC 1.10 Acting on diphenols and related compounds as donors 
11 EC 1.11 Acting on peroxide as acceptor 
12 EC 1.12 Acting on hydrogen as donor 
13 EC 1.13 Acting on single donors with O2 as oxidant and incorporation of paired 
oxygen into the substrate (oxygenases). The oxygen incorporated needs not 
to be derived from O2. 
14 EC 1.14 Acting on paired oxygen donors with O2 as oxidant and incorporation or 
reduction of oxygen. The oxygen incorporated needs not to be derived from 
O2. 
15 EC 1.15 Acting on superoxide as acceptor 
16 EC 1.16 Oxidising metal ions 
17 EC 1.17 Acting on CH or CH2 groups 
18 EC 1.18 Acting on iron-sulfur proteins as donor 
19 EC 1.19 Acting on reduced flavodoxin as donor 
20 EC 1.20 Acting on phosphorus or arsenic as donors 
21 EC 1.21 Acting on X–H and Y–H to form an X–Y bond 
22 EC 1.22 Acting on halogens in donors 
23 EC 1.97 Other oxidoreductases 
Dehydrogenases (e.g. alcohol dehydrogenases, EC 1.1.1.1) are implemented for 
asymmetric reduction of ketones, aldehydes and other derivatives with carbonyl 
groups and for oxidation of alcohols to the corresponding aldehydes or ketones. 
Oxygenases (e.g. Baeyer-Villiger monooxygenases) are frequently used for 
monooxygenations, transformations of ribonucleotides, stereospecific epoxidations, 
and oxidation of esters and lactones (Meyer et al. 2013). 
 
1.6  Alcohol dehydrogenases/Ketoreductases 
Alcohol dehydrogenases (ADHs) belong to the oxidoreductases class (Table 3). 
They catalyse reversible oxidoreduction reactions (Figure 2). The reaction is 
catalysed by the transfer of reducing equivalents between donor and acceptor 
molecules. The reducing equivalents are defined electrons (e.g. produced by 
artificial electron transferring agents or electrodes) or hydride ions (de Torres et al. 
2012; Kim and Yoo 2009). 
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Figure 3. General reaction scheme of oxidoreductases. 
For instance, reduction of the prochiral keto group (acceptor) occurs by the transfer 
of hydride ion from the reduced cofactor (donor) to the carbonyl group yielding an 
alcohol (Figure 3). The reaction in general is highly stereospecific (Patel 2000). 
Depending on the reaction conditions (pH-value) reduction or oxidation is favoured 
yielding alcohols or ketones, respectively.  
 
1.7  Cofactor regeneration 
ADHs require nicotinamide adenine dinucleotide (phosphate) cofactors (NAD(H) 
or (NADP(H)) for their activity (Figure 4).  Since these cofactors are expensive (see 
Table 5), it is uneconomic to apply them in equimolar concentration. To overcome 
cost limitations in large-scale applications cofactor regeneration is essential. 
 
Figure 4. Nicotinamide adenine dinucleotide (phosphate) cofactor. A. Reduced form, B. Oxidised 
form.  
 
Table 5. Cost of nicotinamide adenine dinucleotide cofactors (Biomol GmbH, Hamburg, Germany; 
state: May 2013). 
Cofactor Price EUR/mol 
NAD+ 13 260 
NADH 45 780 
NADP+ 97 588 
NADPH 414 001 
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According to the classification of Chenault and Whitesides (Chenault and 
Whitesides 1987) there are five general methods for cofactor regeneration: 
biological, chemical, electrochemical, photochemical and enzymatic cofactor 
regenerations. The latter is the currently preferred one in industrial applications 
(Chenault and Whitesides 1987; Liu and Wang 2007; Wichmann and Vasic-Racki 
2005) and can be further classified into substrate-coupled and enzyme-coupled 
approaches. 
 
1.7.1  Substrate-coupled approach 
In the substrate-coupled approach only one enzyme for the main reaction and the 
regeneration reaction (Figure 5) is required. Often ethanol or 2-propanol are used as 
co-substrates for the regeneration reaction. During the recycling reaction 
acetaldehyde or acetone, respectively, are formed.  
 
Figure 5.Substrate-coupled cofactor regeneration. 
Some biocatalytical processes employing substrate-coupled cofactor regeneration 
require removal of the co-product formed, since it may affect the activity and 
stability of the enzyme when present in high concentrations (Goldberg et al. 2007). 
The reversibility of the reduction reaction should be also considered. This 
reversibility can occur when pH optima for the reduction and oxidation reaction are 
close to each other or even overlap. Then overall conversion depends on the 
equilibrium constant. High conversions can be achieved by a combination of high 
co-substrate concentrations and smart co-product removal (Stillger et al. 2002). 
There are a number of lab-scale and industrial-scale applications for the substrate-
coupled regeneration approach using alcohol dehydrogenases from 
Thermoanaerobacter brockii (TBADH) (Bastos et al. 1999; Bastos et al. 2002), Candida 
parapsilosis (Stillger et al. 2002), horse liver (Virto et al. 1995), and Lactobacillus brevis 
(Daußmann et al. 2006a; Daußmann et al. 2006b). 
 
1.7.2  Enzyme-coupled approach 
For the enzyme-coupled approach the main reaction is catalysed by one enzyme 
and the regeneration reaction is catalysed by another enzyme (Figure 6). Currently 
various dehydrogenases are commonly applied. Among them are: glucose 
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dehydrogenase from Bacillus cereus (Wong and Drueckhammer 1985; Wong et al. 
1985) and Bacillus subtilis (Hilt et al. 1991). During this reaction glucose (co-
substrate) is oxidised to gluconic acid (co-product), which makes pH control 
necessary. Other well established regeneration enzymes are formate dehydro-
genases from Candida boidinii (Peters et al. 1993b; Zelinski et al. 1999) and 
Pseudomonas sp. (Karzanov et al. 1989; Müller et al. 1978; Tishkov et al. 1993). 
Here formate is oxidised to carbon dioxide as a co-product, which can be easily 
removed from the reaction vessel by evaporation.  
   
Figure 6. Enzyme-coupled cofactor regeneration. 
 
1.8  Mechanism of alcohol dehydrogenases 
For Zn-dependent alcohol dehydrogenases several catalytic mechanisms based on 
the mechanism of horse liver alcohol dehydrogenase (HLADH) are proposed (Auld 
2001; Dunn et al. 1986). Differences in the suggested mechanism are a consequence 
of missing time-resolved structural information about intermediate states during 
catalysis. In addition, the zinc ion is silent in several spectroscopic techniques and 
therefore knowledge about intermediate states is limited (Kleifeld et al. 2003a). 
The mechanism of Zn-dependent alcohol dehydrogenases was solved on the 
example of oxidation catalysed by the enzyme isolated from Thermoanaerobacter 
brockii (TBADH) (Kleifeld et al. 2003a). 
Alcohol dehydrogenase from Thermoanaerobacter brockii (TBADH) is a bacterial 
enzyme that oxidises primary and secondary alcohols to the respective aldehydes 
and ketones in the presence of NADP+, with primary alcohols being less preferred 
(Lamed and Zeikhus 1981). The tetrameric enzyme with a molecular weight of 
37 652 Da per subunit consist of 352 amino acids (Peretz and Burstein 1989). Only 
one single zinc ion per subunit was discovered, which has a catalytic function 
(Bogin et al. 1997). 
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Figure 7. Proposed mechanism of the Zn-dependent alcohol dehydrogenase from Thermoanaerobacter 
brockii (TBADH) on the example of the oxidation of secondary alcohols, where aa1: Cys-
37, aa2: His-59, aa3: Asp-150. a: holoenzyme; the zinc ion remains tetrahedrally 
coordinated when bound to NADP+; b: the first transient complex (TR1) represents the 
coordination of a water molecule before the exchange of Glu-60 residue; c: dissociation of 
the Glu-60 residue results in a tetrahedral  zinc ion with a bound water molecule;  
d: binding of  the substrate (here alcohol);  by formation of alcoholate via a hydride 
transfer the TR2 intermediate is produced; e: product formation; f: dissociation of product, 
cofactor and a water molecule and subsequent binding of the Glu-60 residue yield into the 
initial conformation (according to (Kleifeld et al. 2003a)).  
The tetrahedral coordination sphere of the catalytic zinc ion that directly takes part 
in the reaction mechanism, is coordinated by Asp-150, His-59, Cys-37, and Glu-60 
(Kleifeld et al. 2003b; Korkhin et al. 1998) (Figure 7A). Glu-60 is strictly conserved 
in all members of this ADH-family but has no essential influence on TBADH 
activity, which was confirmed by site-directed mutagenesis studies on this amino 
acid (Kleifeld et al. 2003b). 
The reaction cycle starts with binding of one water molecule to the zinc ion, 
forming a pentacoordinated zinc ion (first pentacoordinated intermediate state, 
transition state TR1) (Figure 7B). Subsequently, the coordinative binding of Glu-60 
is released and the tetrahedral coordination state is restored (Figure 7C). It was 
found that the transition state TR1 has a short life-time, which suggests its role as 
an intermediate for the state TR2. In the next step the substrate (here: alcohol) is 
bound to the zinc ion resulting in the formation of the second pentacoordinated 
transition state of zinc (TR2). Here the reaction between the oxidised cofactor and 
TR2 occurs by transfer of a hydride ion of the substrate molecule to the cofactor 
  
I     Introduction 
 
  
14 
(Figure 7D), resulting in the formation of the reduced cofactor and the product 
(here: aldehyde or ketone) that is released (Figure 7E). Finally, the original state is 
restored by replacing the water molecule in the tetrahedral coordination sphere 
through Glu-60 (Figure 7F) (Kleifeld et al. 2003a). 
Conclusively the oxidation of an alcohol involves a net removal of two hydrogen 
atoms from the substrate (Figure 7C), first a proton abstraction and second a 
hydride ion transfer from the substrate to the cofactor.  
The reverse reaction, the ADH-catalysed reduction of prochiral aldehydes or 
ketones, proceeds in four stereochemical patterns (E1-E4) (Figure 8) depending on: 
 nucleophilic attack of a hydride ion on the sp2-hybridised carbonyl C-atom 
from the re- (E1, E2) or si-face (E3, E4). Re-face is defined with the carbonyl 
group oriented upwards, the small substituent (R1) on the left site and large 
on the right site (R2) (Figure 8);  
 the reduced nicotinamide cofactor contains two diastereotropic hydrogens 
(HS, pro-S and HR, pro-R). Consequently, pro-R (E1, E3) or pro-S (E2, E4) 
hydride attack of the prochiral substrate may result in products with different 
stereoselectivity (Figure 8). 
 
Figure 8. Hydride transfer from cofactor (NAD(P)H) to carbonyl group. ADPR: adenosine 
diphosphate ribose; E1-E4: different kinds of enzymes, where E1 and E3 – pro-R 
configuration, E2 and E4 – pro-S configuration; R1-R2: substituents, where R1 < R2. 
Some known alcohol dehydrogenases can be assigned to one of the four general 
patterns of determine stereoselectivity (E1-E4). For instance: 
• E1 (pro-R/si-face): alcohol dehydrogenases from Pseudomonas sp. (Bradshaw 
et al. 1992a) and Lactobacillus kefir (Bradshaw et al. 1992b); 
• E2 (pro-S/si-face): glycerol dehydrogenase from Geotrichum candidum 
(Nakamura et al. 1990; Nakamura et al. 1992; Nakamura et al. 1988), 
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dihydroxyacetone reductase Mucor javanicus (Dutler et al. 1977; Hochuli et al. 
1977); 
• E3 (pro-R/re-face): alcohol dehydrogenases from yeast (Prelog 1964), horse 
liver (Davies and Jones 1979; Jones 1986; Jones et al. 1976; Lam et al. 1988), 
Thermoanaerobacter brockii (Drueckhammer et al. 1988; Drueckhammer et al. 
1987; Keinan et al. 1986a; Keinan et al. 1986b), and Moraxella sp. (Velonia 
et al. 1999); 
• E4 (pro-S/re-face): is not common among the ADH enzyme family (de 
Wildeman et al. 2007; Fang et al. 1995). 
Most ADHs transfer hydrogen in pro-R conformation to the re-face (E3 pathway) of 
the carbonyl group, defined as the Prelog-rule. By contrast, only few ADHs were 
found that follow the anti-Prelog rule, where the nucleophilic attack occurs from 
the si-face of the carbonyl group (E1 pathway) (Bradshaw et al. 1992a) (Bradshaw 
et al. 1992b). 
 
1.9  Chiral pharmaceuticals 
Chirality and stereochemistry are not new concepts in chemistry, although before 
1992 there was not large interest in stereoselective syntheses. In 1992 FDA (US 
Food and Drugs Administration) and EMA (European Medicines Agency) 
introduced requirements for drug producers to investigate and characterise each 
enantiomer as well as the racemic mixture of all racemic drugs entering the market 
(Richards and McCague 1997). FDA and EMA also recommended the 
redevelopment of registered racemates as single stereoisomers (chiral switch).  
Chirality of drugs is of high importance in terms of possible toxic effects. There are 
several examples, where just one enantiomer is the biologically active one or 
exhibits the desired effect and the other enantiomer is inactive or causes dangerous 
side effects or even where interconversion of one enantiomer into the other one 
occurs. Three examples are:  (I) methadone, (II) warfarin and (III) thalidomide.   
• METHADONE – is a synthetic opioid used for treatment of opioid 
dependency. The racemic mixture of the drug has some side effects such as 
risk of cardiac adverse events and sudden death (Krantz et al. 2009a; Krantz 
et al. 2009b). Opioid activity is found in (R)-methadone (therapeutic effects, 
Figure 9A), whereas (S)-methadone exhibits the mentioned lethal effects 
(Eap et al. 2007). Metabolism of each enantiomer of rac-methadone proceeds 
similar, where the mutual competitive inhibition occurs.  
• WARFARIN – is a drug available in a racemic mixture, where (S)-warfarin 
has a significantly higher therapeutic potential (Scott 1993). It is an anti-
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coagulant agent used for the treatment of thrombosis and thromboembolism. 
Patients treated with warfarin indicate a wide dosing range in order to place 
the narrow therapeutic window between overcoagulation and under-
coagulation (Scott 1993). (R)-warfarin (Figure 9B) is strongly interfering the 
treatment since it inhibits the metabolism of (S)-warfarin.  
• THALIDOMIDE – was introduced as a racemic mixture in the late 1950s as a 
nauseant and sedative drug. Later, it was reported that the (R)-enantiomer 
(Figure 9C) is responsible for sedative affects (Eriksson et al. 2000; Hoglund 
et al. 1998), whereas (S)-enantiomer was found to be teratogenic (Blaschke et 
al. 1979; Heger et al. 1994). Further publications reported that the chiral 
centre in thalidomide is unstable (Reist et al. 1998) resulting in fast 
interconversion of (S)- and (R)-enantiomers in humans (Eriksson et al. 2001). 
Therefore a treatment with only the (R)-enantiomer is still of risk and should 
be evaluated carefully. Nowadays the drug is still used for treatment of 
multiple myeloma (Kropff et al. 2012; Palumbo 2010; Wang et al. 2012; 
Yakoub-Agha et al. 2012), erythema nodosum leprosum (Chen et al. 2010; 
Joglekar and Levin 2004; Villahermosa et al. 2005) and alleviating 
symptoms of HIV (Haslett et al. 1999). Additionally, research is ongoing 
concerning application of thalidomide for the treatment of various kind of 
cancer (Efstathiou and Logothetis 2009; Fanelli et al. 2003; Hashimoto et al. 
2004; Nguyen et al. 1997; Reck and Gatzemeier 2010; Singhal and Mehta 
2001; Zeldis 2005; Zhou et al. 2002). 
 
Figure 9. (R)-enantiomers of chiral pharmaceuticals. A. (R)-methadone, B. (R)-warfarin,  
C. (R)-thalidomide. 
Besides, there are many more similar examples that demonstrate the dangerous 
effects for health and therewith the importance for stereoselective syntheses. As a 
consequence of the costly and time consuming test procedure most companies 
decided to implement new chiral products in optically pure form (Faber and Patel 
2000; Margolin 1993), which resulted in an increase of newly developed single-
enantiomeric drugs significantly (Figure 10) (Agranat et al. 2002; Chir TU-Berlin 
2011). 
There are three possible pathways to gain single stereoisomer of desired compounds 
(Faber 2001; Gadler et al. 2006; Richards and McCague 1997; Turner 2010) (Faber 
2011):  
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• THE CHIRALITY POOL – where the desired chiral centre is provided (e.g. 
isolated from natural sources) and conserved during further catalytic steps; 
• RESOLUTION METHODS – where racemates are separated into single 
stereoisomers; 
• ASYMMETRIC SYNTHESIS – where a single stereoisomer is produced by the 
introduction of an asymmetry centre into a prochiral (non-chiral) molecule. 
 
 
Figure 10. A. Worldwide sales of chiral pharmaceuticals (2000-2009). B. Number of approved drugs 
with priority status of the top 20 US American pharmaceutical companies (based on their 
sales, red columns). The efficiency of research of small pharmaceutical companies (based 
on their research output) of key medicines is much higher than the top 20 (grey columns) 
(Chir TU-Berlin 2011). 
 
1.10  Chiral 1,2-diols as building blocks 
Chiral 1,2-diols find broad application as drugs as well as synthons for 
pharmaceuticals (Figure 11), agrochemicals and chiral catalysts. Currently, chiral 
1,2-diols are successfully implemented as medicines for the treatment of 
neurodegerative diseases (Figure 11A) (Brown et al. 1998; Brown et al. 2001; 
Brown and Ren 2002) or show anti-inflammantory, gastroprotectory and anti-sepsis 
activity (Figure 11B) (Freire et al. 2005; Lee et al. 2003; Song and Son 2003). 
Further, a wide utilisation of 1,2-diols as building blocks is reported for syntheses of 
e.g. cardiovascular agents (Figure 11C) (Lang et al. 1994), (S)-etifoxine (an 
  
I     Introduction 
 
  
18 
anxiolytic and anti-convulsant drug, Figure 10D) (Putman et al. 2007) and anti-
tumor agents (Figure 11E-G) (Ito et al. 1999). The 1,2-diol moiety is also found in 
some anti-fungal antibiotics from the pneumocandin family, for instance: 
pneumocandin A0 (Figure 11H, R
1), echinocandin B (Figure 10H, R2) and 
mulundocandin (Figure 11H, R3). 
 
Figure 11. 1,2-Dihydroxy functions are widely spread among pharmaceuticals and in drug synthons. 
A. drug for treatment of neurodegerative diseases (Brown et al. 1998; Brown et al. 2001; 
Brown and Ren 2002), B. anti-inflammantory, gastroprotector drug with additional anti-
septic activity (Freire et al. 2005; Lee et al. 2003; Song and Son 2003), C. cardiovascular 
agents (Lang et al. 1994), D. building block for the synthesis of (S)-etifoxine  (Putman et 
al. 2007), E-G. anti-tumor agent on Epstein-Barr virus (Ito et al. 1999), H: anti-fungal 
drugs of the pneumocandin type: R1: pneumocandin A0, R
2: echinocandin B, R3: 
mulundocandin.  
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1.11  Production of 1,2-diols 
Production of 1,2-diols can be conducted using chemical or enzymatic methods 
(Figure 12). 
 
Figure 12. Production of 1,2-diols by chemical and enzymatic methods. 
 
1.11.1 Chemical methods 
There are various chemical methods for the production of 1,2-diols. Among them 
are: reduction of α-hydroxy ketones or α-diketones (Figure 12, 1a,b) using hydride 
transfer agents such as NaBH4, LiAlH4 or Zn(BH4)2 (Johnson and Klein 1979; 
McMahon et al. 1981; Noyori et al. 1979; Yamada and Koga 1970), Sharpless 
dihydroxylation of alkenes (Figure 12, 2) (Sharpless et al. 1992), hydrolysis of 
epoxides (Figure 12, 3) (Tokunaga et al. 1997; Wang et al. 2008) or asymmetric 
aldol condensation (Figure 12, 4) (Guillena et al. 2006; Notz and List 2000).  
The chemical reduction of aliphatic α-hydroxy ketones (Figure 12, 1a) to the 
respective 1,2-diols catalysed by aluminium hydride reagents (such as LiAlH4, AlH3, 
[LiAl(OMe)3H] and [LiAl(O-t-Bu)3H]) showed only low stereoselectivities 
(Katzenellenbogen and Bowlus 1973; Bowlus and Katzenellenbogen 1974). Better 
results were achieved by chelation-controlled reduction with Zn(BH4)2 resulting 
mainly in the formation of anti-1,2-diols with higher stereoselectivity compared to 
LiAlH4-catalysed reactions (Nakata et al. 1983). The reactions were shown mainly 
for the reduction of aliphatic α-hydroxy ketones and only few examples of 
araliphatic α-hydroxy ketones were shown with good yields and moderate 
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stereoselecitivies (Bowlus and Katzenellenbogen 1974; Katzenellenbogen and 
Bowlus 1973; Nakata et al. 1983).  
 
Figure 13. Examples of Sharpless dihydroxylation of olefins with excellent stereoselectivities. Alk* 
= Cinchona alkaloid ligands (DHQD or DHQ), PHAL = phtalazine, DHQD = 
dihydroquinidine, DHQ = dihydroquinine (Kolb et al. 1994) 
Most recently a comprehensive investigation of borhydride-catalysed reductions of 
araliphatic α-hydroxy ketones was reported by Husain et al. (Husain et al., 2011). 
They reduced aromatic α-hydroxy ketones with very good conversion but with 
moderate stereoselectivity. Whereas excellent diastereoselectivities (formation of 
anti-1,2-diol, de > 99%) were obtained in several cases using Zn(BH4)2 (Husain et al. 
2011). 
An alternative route is the reduction of α-diketones (Figure 12, 1b) to the respective 
1,2-diols, which was also reported for the production of sterically demanding 1,2-
diols (e.g. benzils). Therefore various chiral ruthenium complexes or organocatalyst 
were employed. Unfortunatelly, the products could be obtained only as mixtures of 
syn- and anti-diastereoisomers (Ikariya and Blacker 2007; Murata et al. 1999). 
Another method especially for the production of 1,2-diols, is the Sharpless 
dihydroxylation of alkenes (Figure 12, 2). Here application of another dangerous 
catalyst, namely OsO4, is required, which is a very expensive, toxic and reactive 
catalyst. Reactions can be successfully applied for the hydroxylation of E-alkenes 
gaining syn-1,2-diols with good stereoselectivities (up to 99% depending on the 
substrate) using chiral ligands (Figure 13) (Kolb et al. 1994). For instance, 
dihydroxylation of styrene (1a) yields the respective 1,2-diol (1b) with high 
stereoselectivity of 97% for both, (R)- and (S)-enantiomers. Similar result were 
obtained with trans-1-phenyl-1-propene (2a) yielding the (1S,2S)-1-phenylpropane-
1,2-diol (2b). Excellent stereoselectivities of > 99% were achieved for the 
dihydroxylation of (E)-1,2-diphenylethene (3a) to (1R,2R)- and (1S,2S)-1,2-
diphenylethane-1,2-diol (3b), respectively (Kolb et al. 1994). In contrast, syntheses 
of anti-1,2-diols are limited by the availability of Z-alkenes, which are hardly 
accessible since respective synthetic methods are less established than for E-alkenes. 
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Moreover, the thermodynamic control favours the lower-in-energy E-alkenes (Kolb 
et al. 1994; Siau et al. 2012). Further, for the synthesis of anti-1,2-diols applying 
Sharpless dihydroxylation, stereoselectivities are generally only moderate (below 
90%) (Kolb et al. 1994). 
Hydrolysis of epoxides (Figure 12, 3) is another method which also often requires 
hazardous and toxic catalysts. The reaction proceeds very often under acidic 
conditions in order to gain vicinal diols. For instance, kinetic resolution of racemic 
epoxides using water and chiral cobalt-based salen complexes gave high yields and 
high enantioselectivities (ee up to 98%) for the resulting 1,2-diols (Tokunaga et al. 
1997). Recently, a modified method of epoxides hydrolysis was reported (Wang et 
al. 2008), where epoxide ring-opening was catalysed by hot water (60-100 °C) 
without any addition of catalysts. Furthermore, Wang et al. showed that addition 
of other nucleophiles such as azides and thiophenol could also effectively open 
epoxide rings in hot water. Although hot water-promoted hydrolysis of epoxides 
gives very high yields (up to 99%), only moderate diastereoselectivities were 
achieved (Wang et al. 2008). 
Further, 1,2-diols can be obtained by aldol condensation (Figure 12, 4). A key 
challenge of the reaction is the simultaneous control of regio-, diastereo- and 
enantioselectivity when asymmetric ketones are applied. The L-proline-catalysed 
aldol condensation gives good conversions (up to 95%) and moderate 
stereoselectivities (dr 20:1) (Notz and List 2000). Guillena et al. presented a 
modified aldol condensation of aldehydes and α-alkoxyacetone. For the reaction a 
combination of L-proline with BINAM-prolinamides were used yielding the anti-
1,2-diol with moderate enantioselectivity (ee up to 85%). Highest regio- and 
diastereoselectivities (ee up to 98%) for the anti-1,2-stereoisomer were gained when 
α-methoxyacetone as a substrate (in DMF at 0 °C) was used (Guillena et al. 2006). 
Finally, a novel synthetic strategy toward the asymmetric synthesis of vicinal diols 
bearing a tertiary centre was developed. The novel method involves (I) the 
dinuclear Mg-catalysed asymmetric addition of ethyl diazoacetate to aldehydes, (II) 
oxidation of the diazo functionality and (III) diastereoselective alkyl transfer of 
various organometallics into chiral β-hydroxy-α-ketoesters in order to gain a 
versatile range of 1,2-diols with high yields (up to 99% depending on the substrate), 
high diastereoselectivities (dr up to > 20:1) and chirality transfer (up to > 99%). 
Chirality transfer is defined as ratio of the enantioselectivity of the product to the 
enantioselectivity of the substrate (Trost et al. 2012). 
Since chemical syntheses of vicinal diols often are conducted with low 
stereoselectivities, there is a necessity to separate all stereoisomers, which is not an 
easy task. The successful separation of racemic 1,2-diols was described for the 1,2-
diphenylethanediol as an example, where several additional chemical steps (e.g. 
synthesis of borate complexes, addition of chiral amino acid derivatives and (S)-
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proline in benzene, treatment with hydrochloric acid) were required in order to gain 
highly stereoselective (1R,2R)-product (de 99%) (Periasamy 1996). 
To conclude: the chemical methods described above have some main drawbacks 
besides the use of hazardous chemicals: often low stereoselectivity and no access to 
all stereoisomers of the compound of interest.  
 
1.11.2 Enzymatic methods 
Enzymatic methods are a good alternative for the stereoselective synthesis of 1,2-
diols avoiding the use of hazardous chemicals and harsh reaction conditions 
(Sheldon 2008).  Three main routes to 1,2-diols are described: (I) reduction of α-
diketones by alcohol dehydrogenases (Figure 12, 5b), (II) reduction of α-hydroxy 
ketones (Figure 12, 5a), and (III) hydrolysis of epoxides by epoxide hydrolases 
(Figure 12, 6) are available. 
Reduction of α-diketones (Figure 12, 5b) by alcohol dehydrogenases is one of the 
common enzymatic methods for the production of vicinal diols. Therefore the 
NADH-dependent diacetyl reductase from Bacillus stearothermophilus was applied. 
The enzyme accepts a large diversity of side chains of various size (mainly aliphatic 
side chains including cyclic compounds) yielding (1S,2S)-diols with high 
enantiomeric excess (ee up to > 98%) (Bortolini et al. 1997). A similar substrate 
spectrum (aliphatic α-diketones) was found for reductions using whole cells of 
Baker’s yeast, Aspergillus niger, Geotrichum candidum, and Rodhotrula rubla (Besse et 
al. 1993; Boutoute et al. 1998). However, these reactions were catalysed with only 
moderate regioselectivities (high formation of α-hydroxy ketones as a side product) 
and enantioselectivities (Boutoute et al. 1998). Furthermore, reduction of diacetyl 
using cells from Pichia farinose IAM 4682 yielded the 1,2-diol with low 
stereoselectivities (Ideka et al. 1996). 
Suitable enzymes for the reduction of α-diketones (such as diacetyl or n-heptane-
2,3-dione) are an alcohol dehydrogenase from Rhodococcus ruber DSM44541 
(isolated yield up tp 93% and de up to > 99%) (Edegger et al. 2006) and the alcohol 
dehydrogenases from Lactobacillus brevis, Thermoanaerobacter sp. and Rhodococcus 
ruber (Kurina-Sanz et al. 2009). The latter catalysing the reduction of long-chain 
aliphatic α-diketones with excellent conversions (up to > 99%) and 
stereoselectivities (ee > 99%). Whereas, short-chain aliphatic α-diketones were 
reduced with lower conversions (higher formation of α-hydroxy ketones as side 
products) and stereoselectivities (Kurina-Sanz et al. 2009). 
Another method for the synthesis of vicinal diols is the hydrolysis of epoxides 
(Figure 12, 6) catalysed by epoxide hydrolases. These enzymes have been found in 
plants (Blée and Schuber 1995), insects (Linderman et al. 1995), bacteria (Mischitz 
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et al. 1995a), filamentous fungi (Morisseau et al. 1997) and mammals (Mueller et al. 
1995; Oesch 1972; Pace-Asciak and Lee 1989; Watabe et al. 1981; Zeldin et al. 
1995). The ring opening leads to the formation of the corresponding anti-configured 
1,2-diol (Orru et al. 1999). Satisfactory sources from bacteria, such as Rhodococcus 
and Nocardia spp. (Kroutil et al. 1997; Mischitz et al. 1995b; Osprian et al. 1997) or 
fungi as for example Aspergillus and Beauveria spp. (Chen et al. 1993; Pedragosa et al. 
1996) have been identified. Bacterium Nocardia EH1 showed almost complete 
enantioselectivity for kinetic resolution of 2-methyl-1,2-epoxyheptane, yielding 
enantiopure (R)-diol and (S)-epoxide (Osprian et al. 1997). 
Also the resolution of racemic monosubstituted, 2,2- or 2,3-disubstituted oxiranes 
was studied, where diverse fungi and bacteria were applied for biotranformations 
displaying high enantioselectivities (Bala and Chimni 2010; Orru et al. 1999).  
Furthermore, Bellucci and coworkers reported highly stereoselective 
biotransformations of racemic epoxides such as (±)-3,4-epoxytetrahydropyran to a 
single diol enantiomer (Bellucci et al. 1989; Hodgson et al. 1996). Most recently, a 
hydrolysis of cyclopentane- and cyclohexane oxides and N-benzyloxycarbonyl-3,4-
epoxypyrrolidine using an epoxide hydrolase from Sphingomonas sp. HXN-200 
afforded the corresponding (R,R)-vicinal diols with high enantioselectivity (ee 86-
93%) and high yields (90-99%) (Wu et al. 2013). Improvement of stereoselectivity of 
the epoxide hydrolase-catalysed reactions to the respective 1,2-diols was recently 
reported by the addition of ionic liquids (Chiappe et al. 2007).  
Stereoselective synthesis of vicinal diols can be also feasible with dioxygenases 
(Figure 12, 7). Oxidation of mono- and poly-cyclic aromatic ring systems (toluene-
derivatives) was reported yielding syn-diols. Diversely mono-substituted benzenes 
were oxidised to the respective syn-2,3-diols with high enantioselectivities (ee 98%). 
The same tendency was observed for the oxidations of di- and poly-diversely 
substituted benzenes, where syn-diols with high enantioselectivities (ee up to 98%) 
were gained (Boyd and Sheldrake 1998). 
Most recently, an enzymatic reduction of diversely substituted α-hydroxy ketones 
(Figure 12, 5a) to the respective 1,2-diols was described using whole cells of Pichia 
glucozyma. Thereby 1,2-diols with high conversions (up to > 80%) and 
diastereoselectivities (syn:anti > 98:2) were obtained. Unfortunately, the respective 
enzyme(s) responsible for these reactions is/are not known yet (Husain et al. 2011). 
Also good conversions (up to 90%) and excellent stereoselectivities (ee up to > 99%) 
were obtained for the reductions of araliphatic diversely substituted α-hydroxy 
ketones to the respective diols using an enzyme system from carrot (Daucus carota) 
(Liu et al. 2012). 
A novel and valuable method is a 2-step enzymatic synthesis of 1,2-diols. The first 
step is the carboligation of two inexpensive aldehydes catalysed by thiamine 
diphosphate (ThDP)-dependent lyase yielding α-hydroxy ketones, which are 
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subsequently reduced in the second step by NAD(P)H-dependent alcohol 
dehydrogenases. This method was first described by Kihumbu in 2002 for the 
production of all four stereoisomers of 1-phenylpropane-1,2-diol (Kihumbu et al. 
2002). Very high enantiomeric and diastereomeric excesses of 98-99% could be 
reached. However, this work was limited to the reduction of (R)- and (S)-2-hydroxy-
1-phenylpropan-1-one (2-HPP) to the all possible stereoisomers of the 1,2-diol 
((1R,2R)-, (1R,2S)-, (1S,2R)- and (1S,2R)-1-phenylpropane-1,2-diol) and it was not 
further assigned to other substrates. 
 
1.11.2.1 First step: carboligation by ThDP-dependent enzymes 
The first step is the carboligation of two inexpensive aldehydes catalysed by a 
thiamine diphosphate (ThDP)-dependent lyase yielding α-hydroxy ketones with 
high regio-, chemo- and enantioselectivity (Figure 14) (Müller et al. 2009; Müller et 
al.; Hailes et al. 2013). 
Within the group of Pohl/Rother at the IGB-1 at Forschungszentrum Jülich GmbH 
a toolbox of ThDP-dependent enzymes was created giving access to a broad 
platform of diversely substituted α-hydroxy ketones with high stereoselectivity 
(Figure 14). The toolbox encompass 23 wild type enzymes (e.g. benzaldehyde lyase 
(BAL), benzoylformate decarboxylase (BFD), acetohydroxyacid synthase (AHAS), 
pyruvate decarboxylase (PDC), etc.) and > 100 variants of them. By smart 
combination of substrates and ThDP-dependent enzyme a desired α-hydroxy 
ketones can be synthesised with excellent regio-, chemo- and enantioselectivity 
(Müller et al. 2009; Müller et al. 2013). 
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Figure 14. Platform of diversely substituted α-hydroxy ketones (adapted and modified from  
(Müller et al. 2009)) 
 
Figure 15. Carboligation of benzaldehyde and acetaldehyde using defined ThDP-dependent enzymes yielding 
mixed α-hydroxy ketone with high enantioselectivity (ee > 99%). 2-HPP = 2-hydroxy-1-
phenylpropan-1-one; PAC = 1-hydroxy-1-phenylpropan-2-one, phenylacetylcarbinol; PfBAL = 
benzaldehyde lyase from Pseudomonas fluorescens (Janzen et al. 2006); PpBFD = benzoylformate 
decarboxylase from Pseudomonas putida and its variants (Gocke et al. 2008; Iding et al. 2000); 
ApPDC = pyruvate decarboxylase from Acetobacter pasteurianus (Rother et al. 2011) and its variant 
(Gerhards et al. 2012); EcAHASI, EcAHASII – acetohydroxyacid synthase isoenzyme I and II, 
respectively from Escherichia coli (Engel et al. 2003); (1) – pyruvate as a donor instead of acetaldehyde.  
For instance, the combination of acetaldehyde and benzaldehyde can yield four 
enantiomeric products, but the main interest in this work is on all four enantiomers 
of the two mixed products (Figure 15).  
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1.11.2.1.1 Benzaldehyde lyase 
Benzaldehyde lyase (BAL) is an enzyme isolated from Pseudomonas fluorescens 
Biovar I. The natural role of the enzyme is catabolic cleavage of aromatic acyloins 
to respective aldehydes, which are next catabolised in β-ketoadipate pathway 
(Janzen et al. 2006). The enzyme requires for its activity two cofactors, thiamin 
diphosphate (0.1 mM) and divalent Mg2+ (2.5 mM) cations (Fraga and Hinrichsen 
1994; Hinrichsen et al. 1994; Janzen et al. 2006).   
BAL is an extremely useful enzyme for biotransformations, since it is able to 
catalyse lyase and ligase reactions (cleavage and formation of benzoin, respectively). 
Detailed biochemical characterisation of the enzyme revealed that the enzyme is 
stable between pH 6 to 8, which is the pH-optimum for the lyase and ligase activity. 
Furthermore, BAL shows extremely high initial rate activities, a broad substrate 
scope and excellent stereoselectivities (ee > 99% depending on substrates) (Janzen et 
al. 2006).  
 
1.11.2.1.2 Benzoylformate decarboxylase  
Benzoylformate decarboxylase (BFD) was found in the mandelate catabolism of 
bacteria such as Pseudomonas putida, Acinetobacter calcoaceticus and Pseudomonas 
aeruginosa (Barrowman and Fewson 1985; Barrowman et al. 1986; Hegeman 1970). 
The enzyme is responsible for the non-oxidative decarboxylation of benzoylformate 
to benzaldehyde. Besides BFD catalyses also the carboligation of benzaldehyde 
(upon decarboxylation of benzoylformate) and acetaldehyde (Iding et al. 2000; 
Wilcocks et al. 1992). BFD shows similar pH-optima to BAL: for the carboligation 
starting from benzoylformate and acetaldehyde a pH-optimum between 6.0 and 8.5 
was found, whereas for the pH-optimum is shifted to 7.5-8.5, if benzaldehyde and 
acetaldehyde are used as substrates (Iding et al. 2000).  The carboligation of two 
molecules yields valuable α-hydroxy ketones with high stereoselectivity (up to 
ee > 99%) (Iding et al. 2000). The carboligation of benzaldehyde and acetaldehyde 
gives (S)-2-HPP with high enantioselectivity (ee 92-94%) (Iding et al. 2000; 
Wilcocks et al. 1992). Meanwhile several variants of BFD with improved 
stereoselectivity for the production of (S)-2-HPP (ee 98%) were prepared, namely 
BFD-L461A and BFD-L461G (Demir et al. 2001; Gocke et al. 2008; Iding et al. 
2000; Lingen et al. 2003).  
 
1.11.2.1.3 Acetohydroxyacid synthase  
Acetohydroxyacid synthases are key enzymes in plants, fungi and bacteria, which 
catalyse de novo synthesis of the branched-chain amino acids (Bar-Ilan et al. 2001; 
Chipman et al. 1998; Chipman et al. 2005; McCourt and Duggleby 2005). 
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Isoenzyme I of acetohydroxyacid synthase (AHAS-I) isolated from Escherichia coli is 
a ThDP-dependent enzyme, which requires besides ThDP, Mg2+ ions and FAD for 
its activity. The enzyme catalyses the carboligation of an α-keto acid (acceptor, 
here: pyruvate) and aldehyde (donor, here: benzaldehyde) yielding an (R)-α-
hydroxy ketone (here: PAC) with very high enantioselectivity (ee > 98%) (Engel et 
al. 2003; Engel et al. 2004a; Engel et al. 2004b; Engel et al. 2005: Vinogradov et al. 
2005; Vinogradov et al. 2006). The pH-optimum for carboligation of pyruvate and 
benzaldehyde was found at pH 6.5-8.0 (Chien et al. 2010). Besides, carboligation 
starting from two aldehydes such as acetaldehyde and benzaldehyde is catalysed 
with significantly lower activity (Schmitz 2012).  
 
1.11.2.1.4 Pyruvate decarboxylase 
Pyruvate decarboxylase from Acetobacter pasteurianus (ApPDC) is an enzyme 
responsible for the oxidative metabolism of lactic acid to acetaldehyde and carbon 
dioxide. Acetaldehyde is subsequently oxidised to its final product, acetic acid 
(Rother et al. 2011). Recently it was found that the (R)-selective enzyme is capable 
to catalyse the synthesis of (R)-α-hydroxy ketones. Genetic modification of the wild 
enzyme yielded the variant ApPDC E469G that gave access to (S)-α-hydroxy 
ketones using aliphatic donor aldehydes and benzaldehyde as the acceptor. Best 
results were obtained with propanal as the donor (ee 89%) under the conditions 
tested (Rother et al. 2011). 
 
1.11.2.2 Second step: oxidoreduction by alcohol dehydrogenases 
The proof-of-principle of combination of ThDP-dependent enzymes with ADHs 
was already shown by Kihumbu for the production of four stereoisomers of 
1-phenylpropane-1,2-diol in 2-step 2-pot synthesis through reduction of the 
intermediate, 2-HPP (Kihumbu et al. 2002). 
An extended investigation of the substrate scope of available oxidoreductases with a 
focus on the reduction of diversely substituted α-hydroxy ketones was first 
conducted in this thesis. 
 
1.11.2.2.1 Carbonyl reductase from Candida parapsilosis  
Carbonyl reductase from Candida parapsilosis (CPCR) was first isolated from the 
strain DSM 70125 and biochemically characterised by Peters et al. (Peters et al. 
1993a). The same enzyme was later isolated by Yamamoto et al. from a related 
strain IFO 0369 and expressed in E. coli (Yamamoto et al. 1999). CPCR consists of 
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336 amino acids per subunit (Yamamoto et al. 1999) and forms a dimer. The 
carbonyl reductase is an NADH- and Zn2+-dependent enzyme, which belongs to the 
medium-chain dehydrogenase family (Jakoblinnert et al. 2012). The (S)-selective 
enzyme displays a broad substrate range and therefore is employed for a number of 
various processes such as production of valuable alcohols (Matsuyama et al. 2011), 
hydroxy esters (Peters et al. 1993c) and propargylic alcohols (Schubert et al. 2001).  
Furthermore, the enzyme was successfully employed for biotransformations in an 
enzyme membrane reactor (Laue et al. 2001), an enzyme emulsion reactor (Liese et 
al. 1998) and a biphasic reactor (van den Wittenboer et al. 2009). Most recently, the 
enzyme overexpressed in E. coli was implemented as a whole cell biocatalyst for 
biotransformation in neat organic substrates with excellent conversions yielding up 
to 500 g L–1 of enantiopure alcohol (Jakoblinnert et al. 2011). 
 
1.11.2.2.2 ADH from Flavobacterium frigidimaris 
The NAD(H)-dependent medium-chain dehydrogenase (MDR) was isolated from 
the psychrotolerant Flavobacterium frigidimaris (FADH). The enzyme consists of 344 
amino acids per subunit and forms a tetramer. Furthermore, the enzyme contains 
two Zn2+-ions per subunit (see chapter 1.8). FADH shows a broad temperature 
range for activity between 0 °C and 85 °C with an activity maximum at 70 °C. The 
(S)-selective enzyme displays a broad substrate range for the reduction of aliphatic 
aldehydes and ketones (Kazuoka et al. 2007). 
 
1.11.2.2.3 ADH from horse liver  
Commercially available HLADH is a NAD(H)-dependent medium-chain 
dehydrogenasase. The enzyme consists of 374 amino acids per subunit (Jörnvall  
1970) and forms a dimer (Ramaswamy et al. 1994). HLADH contains two Zn2+-
ions per subunit (one structural and one catalytical) (see chapter 1.8) (Bränden et al. 
1973; Eklund et al. 1976). The (S)-selective enzyme is frequently used e.g. for 
reductions of aldehydes (Bowen et al. 1986; Bradshaw et al. 1992c; Giacomini et al. 
2007), ketones (Jones and Schwartz 1981; Jones and Takemura 1982; Krawczyk 
and Jones 1989; Lam et al. 1988; Shigematsu et al. 1995; Willaert et al. 1988), 
oxidation of alcohols (Adolph et al. 1991; Dalziel and Dickinso 1966; Jones and 
Lok 1979; Lemiere et al. 1988; Merritt and Tomkins 1959) and esterase reaction 
(Tsai 1982). HLADH was successfully implemented for numbers of cofactor 
regeneration processes (Itozawa and Kise 1993; Itozawa and Kise 1995; Virto et al. 
1995). Furthermore, the enzyme in immobilised form was successfully used for 
biocatalysis (Itozawa and Kise 1995; Sotolongo et al. 1999). 
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1.11.2.2.4 ADH from Lactobacillus brevis  
The NADP(H)-dependent short-chain dehydrogenase (SDR) isolated from 
Lactobacillus brevis (LBADH) consists of 241 amino acids per subunit and forms a 
tetramer (Riebel 1996). LBADH requires for its activity Mg2+-ions (Niefind et al. 
2003; Niefind et al. 2000; Schlieben et al. 2005). The enzyme shows pH-optimum 
for reduction at pH 6.5-8.5, whereas optimum for oxidation is between pH 7-10 
(Kulishova 2010). The (R)-selective enzyme (Niefind et al. 2003; Niefind et al. 
2000; Schlieben et al. 2005) has a broad substrate scope including linear and 
branched aliphatic as well as aromatic aldehydes and ketones, propargylic and 
allylic ketones, diketones, ketoesters and acetophenone and its derivatives (Leuchs 
and Greiner 2011). LBADH is also active towards α-hydroxy ketones (Kihumbu et 
al. 2002). Further, the enzyme is used in industrial processes, e.g. for the production 
of ethyl-(3R)-hydroxybutanoate (Daußmann et al. 2006b; Liese 2006). 
 
1.11.2.2.5 ADH from Ralstonia sp. 
Alcohol dehydrogenase from Ralstonia sp. (RADH) consists of 249 amino acids per 
subunit and belongs to a short-chain dehydrogenases family (Lavandera et al. 
2008a). The enzyme was found to be specifically useful for reductions of bulky-
bulky ketones containing two sterically demanding substituents (Lavandera et al. 
2008a). The reductions employing the recombinant enzyme from E. coli were 
catalysed with activities up to 17.4 μmol h–1 g–1 and moderate stereoselectivities 
(ee 40-95%), depending on the substrate and the implemented cofactor regeneration 
system (Lavandera et al. 2008c). Substrate-coupled cofactor regeneration was 
optimised using ethanol (10 vol%) and 2-propanol (5 vol%) at pH 7.5 and pH 7.0, 
respectively (Lavandera et al. 2008c). Better activities up to 32.4 μmol h–1 g–1 
(ee > 99%) were obtained with bulky-bulky ketones and glucose dehydrogenase 
(GDH) for cofactor regeneration (Lavandera et al. 2008a). 
In purified form the enzyme with streptavidine tag (strep-RADH) was only 
implemented for the reduction of aldoxime to the respective alcohol proving first 
chemo-promiscuous activity of RADH (Ferreira-Silva et al. 2010).  
Biochemical characterisation of isolated RADH was first performed in frame of this 
thesis. 
 
1.11.2.2.6 ADH from Sphingobium yanoikuyae 
A further well suited enzyme for the reduction of bulky-bulky ketones is alcohol 
dehydrogenase from Sphingobium yanoikuyae (SADH) (Lavandera et al. 2008b; 
Lavandera et al. 2008c). As RADH, the enzyme belongs to the short-chain 
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dehydrogenases superfamily and consists of 262 amino acids per subunit 
(Lavandera et al. 2008b). 
The recombinant enzyme overexpressed in E. coli catalyses the reduction of 
sterically hindered ketones with higher activities (up to 18.6 μmol h–1 g–1) than 
RADH and moderate stereoselectivities (ee 59-97%), depending on the reduced 
substrate and implemented cofactor regeneration system (Lavandera et al. 2008c). It 
was found that for SADH-catalysed reactions suitable co-substrates for cofactor 
regeneration are 2-propanol (5 vol%) and ethanol (5 vol%) with pH-optima of 7.0 
and 8.0, respectively (Lavandera et al. 2008c). 
Lyophilised E. coli cells containing overexpressed SADH were implemented 
successfully for dynamic kinetic resolution of rac-methylcarbinols, e.g. 
hexanophenone with good to very good enantiomeric excesses (ee 89% (S) and 
ee 97% (S) using ethanol and 2-propanol for cofactor regeneration, respectively) 
(Lavandera et al. 2008b). As with RADH detailed biochemical characterisation of 
the purified enzyme is still missing. 
 
1.11.2.2.7 ADH from Thermoanaerobacter brockii 
The alcohol dehydrogenase isolated from Thermoanaerobacter brockii (TBADH) 
consists of 352 amino acids per subunit and is a medium chain, Zn2+- and 
NADP(H)-dependent enzyme (see chapter 1.8) which forms a tetramer (Peretz and 
Burstein 1989; Peretz et al. 1997). The enzyme is applied for biotransformations of 
chloro-substituted aliphatic ketones (Keinan et al. 1986a; Keinan et al. 1986b) and 
furanyl ketones (Drueckhammer et al. 1988). TBADH is used for industrial 
applications mainly for cofactor regeneration (enzyme-coupled approach) (Bastos et 
al. 1999; Bastos et al. 2002; Keinan et al. 1986b; Korkhin et al. 1998; Röthig et al. 
1990), since it displays high activity towards aliphatic primary and secondary 
alcohols (Lamed and Zeikus 1981). Therefore TBADH was also tested for cofactor 
regeneration in the present thesis. 
 
1.11.2.2.8 ADH from Thermoanaerobacter sp.  
The (S)-selective alcohol dehydrogenase isolated from Thermoanaerobacter sp. 
(ADHT) is another Zn2+- and NADP(H)-dependent medium-chain dehydrogenase, 
which consists of 352 amino acids per subunit (Daußmann and Hennemann 2009). 
The enzyme displays broad substrate scope toward aldehydes and ketones 
(Daußmann and Hennemann 2009) and it was employed for biotransformations in 
isolated and immobilised form (Trivedi et al. 2005; Trivedi et al. 2006) for the 
stereoselective production of (R)- and (S)-allylic alcohols (chemoenzymatic method) 
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(Sgalla et al. 2007), 1,2-diols (Kihumbu et al. 2002) and (S)-1-phenylethanol, 
respectively (Trivedi et al. 2005; Trivedi et al. 2006). 
 
1.11.2.2.9 ADH from Thermus sp. 
The (S)-selective alcohol dehydrogenase from Thermus sp. (TADH) consists of 347 
amino acids per subunit, which classifies the enzyme as an MDR (medium-chain 
dehydrogenases/reductases) protein superfamily (Jörnvall et al. 2010). In the 
sequence of TADH a typical zinc-binding motif was found. Furthermore, the 
enzyme is strongly inhibited by addition of EDTA indicating metal-dependency. 
The crystal structure of TADH is still missing and therefore the metal-dependency 
still could not be confirmed. TADH is an NAD(H)-dependent enzyme with broad 
substrate range including aliphatic and aromatic aldehydes, aliphatic and cyclic 
ketones. By contrast, aromatic ketones are reduced with significantly lower 
velocities. These reactions result in formation of (S)-alcohols with high 
stereoselectivity (ee > 99%) (Höllrigl et al. 2008). 
 
1.12 Synthetic cascade reactions 
Cascade reactions are common in nature. In metabolic pathways of living cells, a 
synchronised regulation of a number of enzymatic reactions without isolation of 
intermediates occurs.   
According to Ricca et al. (Ricca et al. 2011) a synthetic biocatalytic cascade reaction 
is a reaction system, where two or more reactions are carried out concurrently in 
the same reaction vessel using at least one biocatalyst. This encompasses multi-
enzymatic, chemo-enzymatic, and enzyme-initiated spontaneous sequences (Ricca 
et al. 2011). Modular cascade processes have many advantages, but also some 
drawbacks, which are summarised in Table 6. 
Most importantly, with synthetic cascade reactions in one pot economic and 
environmental benefits, such as reduction of intermediate steps or waste production, 
can be gained. Besides, cascade reactions give the opportunity to shift reaction 
equilibriums to the direction of the desired product. Therewith higher space-time 
yields (Junceda 2008) can be reached, which is not possible in time separated multi-
step processes.  Apart from these significant advantages, the main drawbacks of 
multi-step modular cascade reactions are highly varying reaction rates of different 
biocatalysts in one pot. Therefore reaction engineering is often a crucial step in 
order to achieve reasonable conversions for each step of the cascade.
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Table 6. Advantages and disadvantages of modular cascade reactions conducted concurrently in one 
pot (Junceda 2008). 
Advantages Disadvantages 
– Less intermediate steps 
– Less solvent and reaction volume 
– Shorter cycle times 
– Higher space-time yields 
– Less waste (atom economy) 
– Catalysts are often incompatible with each 
other 
– Reaction rates may be very different  
– Difficulties of finding optimum conditions  
(pH, temperature, solvent, etc.) 
Depending on the process used, four cascade “designs” can be distinguished 
(Figure 16): 
A. LINEAR CASCADE – is a classical approach of the cascade reaction, where a 
single substrate is transformed via one or more intermediate steps to a single 
product (Figure 16A). This kind of domino reaction helps to reduce waste 
and save time required for purification of intermediates (Ricca et al. 2011). 
Linear cascade can proceed in: 
 SEQUENTIAL MODE – where addition of catalysts to the reaction 
vessel proceeds subsequently; 
 SIMULTANEOUS MODE – where catalysts are added to the reaction 
vessel at the same time; 
 
B. ORTHOGONAL CASCADE – the substrate conversion to the desired product is 
coupled with additional reactions in order to recycle cofactors or 
cosubstrates, or to remove by-products (Figure 16B) (Ricca et al. 2011). 
 
C. CYCLIC CASCADE – one out of a mixture of substrates (e.g. racemate) is 
selectively transformed to an (prochiral) intermediate, which is subsequently 
converted back to the starting material (one of enantiomer) (Figure 16C). By 
repeated reactions one enantiomer is accumulated, while the other one is 
subsequently reverted into the starting substrates (Ricca et al. 2011).  
 
Figure 16. Cascade reactions can be classified by four different designs. A. Linear cascade;  
B. Orthogonal cascade, C. Cyclic cascade, D. Parallel cascade, (Ricca et al. 2011); 
Abbreviations: S = substrate, I = intermediate, P = product, X = co-substrate, Y = co-
product or by-product, Z = another product. 
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D. PARALLEL CASCADE – two different substrates are simultaneously converted 
to two valuable products of interest (Figure 16D). These reactions are very 
often catalysed in the presence of co-substrates or cofactors (Ricca et al. 
2011).  
 
1.13 Reaction/Process engineering 
Enzyme reaction engineering allows identification of optimal reaction parameters 
for the multi-enzymatic cascades. Since cascade reactions combine various enzymes 
with different features, it is necessary to find optimal conditions for these enzymes 
(e.g. pH, temperature, enzyme-, substrate-, cofactor concentrations) in order to gain 
highest possible productivity. 
Enzyme-catalysed biotransformations have to be well planned. Some requirements 
have to be considered, such as: 
 PRODUCT – which should be obtained in high optical purity and (optimally) 
without by-product formation; 
 ENZYME – its applicability for the cascade has to be confirmed in advance. It 
does not only need to accept the substrate of interest, but further has to be as 
active, stable and selective as possible. These data have to be available in 
advance to select an appropriate biocatalyst; 
 SUBSTRATES – substrate selection strongly depends on its availability and price 
(Drauz and Waldmann 2002). Further, a smart selection may result in the 
development of desired cascade types, e.g. recycling cascades with in situ co-
product removal, what was conducted in frame of this thesis. 
The goal of the reaction engineering is to find conditions where following 
requirements are at least partially fulfilled: 
 high reaction selectivity 
 high optical purity of the product 
 high space time yield/conversions (productivity) of the optimised reaction 
 low enzyme and cofactor use per mass unit of product (Drauz and 
Waldmann 2002) (Table 2). 
Generally, process development consists of three steps, including investigation of 
the (I) reaction system, (II) reaction kinetics, and (III) optimal process engineering 
and reactor design (Figure 17). 
  
I     Introduction 
 
  

 
Figure 17. Steps of process optimisation in enzyme reaction engineering (Drauz and Waldmann 
2002, modified). 
I. INVESTIGATION OF THE REACTION SYSTEM can be subdivided into two parts: 
a. Enzyme properties have to be tested regarding: 
i. Activity, selectivity and stability, concerning pH, temperature, 
suitable buffer, and additives (e.g. metal-ions as stabilisation 
agents); 
ii. Optimal substrate, product, co-substrate (e.g. for cofactor 
regeneration) concentrations. Here, additionally the enzyme 
activity and possible sur-plus inhibition should be investigated;  
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b. Other features of the reaction system (e.g. equilibrium constant of 
reversible reactions, pH- and temperature-effects on substrate and 
products solubility, etc.). 
 
II. INVESTIGATION OF REACTION KINETICS. Here a detailed analysis of kinetic 
parameters should be performed under optimised reaction conditions 
described in point I. Once all required kinetic data are available, mathematical 
reaction modelling should be applied in order to calculate theoretical 
conversions of investigated process. Mathematical reaction modelling can be a 
helpful tool to detect bottlenecks during process optimisation. 
 
III. INVESTIGATION OF OPTIMAL PROCESS ENGINEERING AND REACTOR DESIGN 
is the reactor design and evaluation of the optimal process mode (e.g. type of 
cascade). 
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Abstract 
Alcohol dehydrogenases (ADHs) are applied in industrial synthetic chemistry for the 
production of optically active secondary alcohols. However, the substrate spectrum of 
many ADHs is narrow, and few, for example, are suitable for the reduction of prochiral 
ketones in which the carbonyl group is bounded by two bulky and/or hydrophobic 
groups; so-called ‘bulky-bulky’ ketones. Recently two ADHs, RasADH from Ralstonia 
sp. DSM 6428, and SyADH from Sphingobium yanoikuyae DSM 6900, have been 
described, which are distinguished by their ability to accept bulky-bulky ketones as 
substrates. In order to examine the molecular basis of the recognition of these substrates 
the structures of the native and NADPH complex of RasADH, and the NADPH 
complex of SyADH have been determined and refined to resolutions of 1.5, 2.9 and 2.5 
Å respectively. The structures reveal hydrophobic active site tunnels near the surface of 
the enzymes that are well-suited to the recognition of large hydrophobic substrates, as 
determined by modelling of the bulky-bulky substrate n-pentyl phenyl ketone. The 
structures also reveal the bases for NADPH specificity and (S)-stereoselectivity in each 
of the biocatalysts for n-pentyl phenyl ketone and related substrates. 
 
Introduction 
Alcohol dehydrogenases (ADHs) have been employed for many years in both academic 
and industrial groups for the asymmetric reduction of prochiral carbonyl groups to 
optically active secondary alcohols [1,2]. The natural diversity of ADHs has ensured 
that enzymes encompassing a host of catalytic characteristics have been made available 
for applications.  Hence there are ADHs that offer (R)-[3] or (S)-[4] selectivity, 
thermostability [5,6] and an impressive tolerance to organic solvents that allows the 
enzymes to be used in the presence of high substrate concentration [7] or even neat 
substrate itself [8]. One such niche application of ADHs is served by a subgroup of 
these enzymes that transforms prochiral ketones that feature large hydrophobic groups 
on either side of the carbonyl group; ‘bulky-bulky’ ketones.   
As part of a culture collection screening programme, Kroutil and co-workers described 
the cloning, expression and application of an ADH from Ralstonia sp. DSM 6428, 
which was able to accept these bulky-bulky ketones as substrates [9]. The Ralstonia 
ADH (RasADH from hereon) enzyme was applied to the reduction of n-butyl phenyl 
ketone and n-pentyl phenyl ketone 1 with (S)-enantioselectivity and with e.e.s of up to 
>99% (Figure 1) [9]. The excellent enantioselectivity was also extended to bulky-small 
ketones such as acetophenone.  RasADH has subsequently been characterised in some 
detail by one of our groups [10]. The enzyme was reported to be of the short chain 
dehydrogenase (SDR) family, with a subunit molecular weight of 26.7 kDa (249 amino 
acids) and it was suggested that three subunits of the enzyme associated to form a trimer 
in solution. RasADH exhibited a broad pH optimum for the reductive transformation of 
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benzaldehyde and had a half-life of 80 h at 25°C. The stability of the enzyme could be 
augmented by the addition of calcium ions. RasADH was subsequently also applied to 
the reduction of -hydroxy ketones [11] and in the dynamic kinetic resolution (DKR) of 
-alkyl--hydroxyesters such as 3 (Figure 1) to give (2S, 3S)- products of type 4 [12]. 
Further screening of microbial culture collections for the reduction of bulky-bulky 
ketones revealed a strain of Sphingobium yanoikuyae DSM 6900 that was also able to 
reduce n-pentyl phenyl ketone 1 to the (S)-alcohol 2 in up to 97% e.e. [13]. This short 
chain dehydrogenase, named SyADH, was isolated and the relevant gene cloned and 
expressed, and subsequently used for the non-selective oxidation of some small 
prochiral alcohols [14]. Like RasADH, SyADH has also recently been employed in the 
DKR of -alkyl--hydroxyesters such as 5 [12], in this case to give (2R, 3S)- diol 
products 6 with excellent d.e.s and e.e.s 
RasADH and SyADH therefore present distinctly useful biocatalysts as they catalyse 
the transformation of sterically challenging substrates and with, in some cases, 
complementary stereo- and diastereo-selectivities to established ADHs. In the case of 
each of these enzymes, knowledge of their three-dimensional structure would not only 
provide information for the first time on the determinants of bulky-bulky ketone 
recognition in such ADHs, but also serve to inform the engineering of other ADHs for 
transformation of those substrates, or for the expanded substrate specificity of RasADH 
and SyADH themselves. In this report, we present the X-ray crystal structures of the 
apo- and NADPH-complex of RasADH at 1.5 Å and 2.9 Å resolution respectively, and 
also the structure of the NADPH complex of SyADH at 2.5 Å resolution. These 
structures reveal the hydrophobic characteristics of the active site(s) that allow 
accommodation of large hydrophobic substrates, and also shed light on the determinants 
of cofactor specificity in these ‘bulky-bulky’ ADH enzymes. 
 
Results and Discussion 
Structure of RasADH 
RasADH was expressed from a strain of E. coli BL21 (DE3) that had been transformed 
with the gene encoding RasADH ligated into the pET-YSBLIC-3C vector [15]. After 
purification using nickel affinity and gel filtration chromatography, the pure protein was 
initially concentrated to 8 mg mL-1 and during this process problems with precipitation 
were encountered, but these were successfully addressed through the inclusion of both 
NaCl and glycerol in the cell resuspension and protein purification buffers (see 
Experimental Section). Gel filtration studies on the protein derived in this way were 
suggestive of a tetramer of RasADH monomers in solution, rather than the trimer 
suggested by earlier studies [10]. 
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Crystals of RasADH were obtained in two forms, each of which was soaked with 10 
mM NADPH before testing diffraction quality. It was found that the first form 
diffracted to a resolution of 1.5 Å with a C21 space group. Data collection and 
refinement statistics can be found in Table 1. The structure of RasADH was solved by 
molecular replacement using a monomer of a ‘probable dehydrogenase protein’ from 
Rhizobium etli CFN42 (55% sequence identity with RasADH; PDB code 4FGS) as a 
model. In the structure solution there were four monomers A-D in the asymmetric unit, 
which made up a tetramer (Figure 2a), a quaternary association common to some other 
short-chain ADHs such as the carbonyl reductase from Candida parapsilosis (PDB 
code 3CTM, [16]) and levodione reductase from Corynebacterium aquaticum (1IY8, 
[17]). 
Each monomer of RasADH (Figure 2b) was made up of a classical Rossmann fold with 
a central -sheet composed of seven-strands:  1 (residues 8-13); 2 (33-37); 3 (54-
58); 4 (83-87); 5 (131-135); 6 (174-180) and 7 (239-242). The -sheet was 
surrounded by six alpha helices: 1 (residues 17-30); 2 (40-50); 3 (64-77);  4 (101-
126); 5 (148-168) and 7 (217-228). A further helix, the sixth in sequence order 6 
(195-208, as revealed by the NADPH complex structure – vide infra), was largely 
missing from the density in the apo structure of RasADH.  This helix was part of a 
sequence of residues in the region of Thr185 to Phe205 that in each subunit could not be 
modelled (although residues Glu200 to Lys204 were present in subunit ‘C’). A possible 
role for this helix is discussed below.  Notwithstanding helix 6, the overall fold of the 
RasADH monomer (Figure 2b) is well-conserved amongst SDR structures; a 
superimposition of the ‘A’-chain of RasADH with that of a monomer of 4FGS gave an 
rmsd of 0.71 Å over 240 Catoms. The RasADH monomer is most similar to 4FGS 
and a putative oxidoreductase protein from Sinorhizobium meliloti 1021, (PDB code 
4ESO; with 41% sequence identity to RasADH), as determined by analysis using the 
DALI server [18], with rmsd values for the latter structure 1.4 Å. over 250 residues.  In 
this first, higher resolution, structure of RasADH no residual density in the omit map 
corresponding to the NADP(H) cofactor could be observed in the putative active site of 
the enzyme.  
A monomer of RasADH (for example, subunit ‘A’) closely associates with its 
neighbours ‘C’ and ‘B’, and to a lesser extent, ‘D’, to form the tetramer. Subunit ‘A’ 
makes a contact surface area of 1540 Å2 with subunit ‘C’, as calculated using PISA [19], 
with interactions dominated by the reciprocal association of helices 7, including 
stacking interactions between Phe226 residues of each subunit, and strands 7, which 
are largely governed by hydrophobic side-chain interactions. ‘A’ also closely interacts 
with subunit ‘B’, with a calculated shared interface of 1670 Å2. This pair of monomers 
interacts most closely through reciprocal interactions between helices 4 and 5, 
including the indole nitrogen of Trp164 of ‘A’ with the carboxylate side chain of ‘B’ 
Asp148 and a salt bridge between the side-chains of ‘A’ Asp105 and ‘B’ Arg 113.  
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The other crystal form of RasADH diffracted more poorly, to a resolution of 2.9 Å, and 
in the same C21 space group as the apo-enzyme. Using the monomer of the apo-
structure as a model, the structure solution in this instance yielded six monomers in the 
asymmetric unit, representing one full tetramer and one half-tetramer. In this case, each 
monomer featured extensive density in the omit map in the active site that was 
representative of the cofactor NADPH at full occupancy. In addition, density for the 
helix  in the region of Thr185 to Phe205 was now largely complete, and could be 
modelled, save for one or two residues in the region of Val191. Chain ‘F’ was complete, 
however. The loop density in the NADPH complex confirmed that the loop appears to 
act as lid for the active site, closing over the cofactor in the holo-form of the enzyme 
(Figure 2b). 
 
Structure of SyADH 
SyADH was also subcloned into the pET-YSBLIC-3C vector, and was again expressed 
well in the soluble fraction of the BL21 (DE3) strain of E. coli. In this case however, gel 
filtration analysis suggested that SyADH was predominantly a dimer in solution. 
Crystallisation of SyADH followed cleavage of the hexahistidine tag as described in the 
Experimental Section.  Crystals were of the P21 space group. The structure was solved 
using the programme BALBES [20], which selected a monomer of the NADPH-
dependent blue fluorescent protein from Vibrio vulnificus (3P19; 25% sequence identity 
with SyADH) as a model. The solution featured five dimer pairs in the asymmetric unit 
(Figure 3a).   
The monomer of SyADH (Subunit ‘A’ will serve as the model for the description 
below), again features the characteristic Rossmann-type fold, again featuring a central 
-sheet of seven strands: 1 (residues 6-11);  2 (31-34);  3 (56-58);  4 (82-88);  5 
(134-138);  6 (177-181) and  7 (224-225). In SyADH, the sheet is surrounded by 
seven -helices:  1 (residues 15-27); 2 (38-52) 3 (66-78); 4 (102-130); 5 (151-
171) 6 (190-194) and 7 (207-220). A last helix, 8, stretching from residues 234-238, 
is at the C-terminus of the protein and participates in pronounced monomer-monomer 
(‘A’/’B’) interactions, helping to form the dimer (Figure 3b). Electron density allowed 
the modelling of residues Thr3 or Leu 4 through Tyr258 in all subunits, with only 
residue Asn199 not modeled in subunits ‘I’ and ‘J’, owing to poor electron density. The 
monomer of SyADH was most similar to monomers of clavulanic acid dehydrogenase 
from Streptomyces clavuligerus (PDB code 2JAH; 26% sequence identity with SyADH; 
rmsd 2.2 Å over 245 Catoms) [21] and sepiapterin reductase from Chlorobium 
tepidum (PDB code 2BD0; 25% sequence identity with SyADH; rmsd 2.4 Å over 240 
Catoms) [22]. The overall structural fold of the monomer of SyADH was very similar 
to that of 2JAH, save for a loop region Phe218-Leu223 between 7 and 7 in SyADH 
which was longer in 2JAH (Ala227 –Val236). Monomer ‘A’ was calculated to form an 
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interface of 3700 Å2 with its dimer partner, subunit ‘B’, as calculated using PISA [19]. 
The dimer is stabilised by reciprocal interactions between residues in helices 8, 
including a salt bridge between the side-chain of residues Asp248 and Arg234 in each 
subunit, but also reciprocal interactions between 4 and 5, which are structurally 
homologous with helices 4 and  in RasADH, described above. 
 
The substrate binding sites 
The active site of RasADH is a hydrophobic tunnel that is formed at the top of the 
central -sheet of the Rossmann fold as seen in Figure 2b and Figure 4, and is partially 
covered by helix 6 in the NADPH-complex structure. The nicotinamide ring of 
NADPH sits at the base of this tunnel, lined by residues Tyr150 (the likely proton donor 
to a nascent alcohol in the reductive ADH-catalysed reaction [23]), Ser137, Phe205, 
Leu144, Leu142, Val138, Tyr150, Ile91, His147 and Gln191. The strict specificity for 
the phosphorylated cofactor NADPH is governed by interactions of adjacent arginine 
residues Arg38 and Arg39 and Asn15, with Arg38 also participating in -stacking 
interactions with the adenine ring. The interactions with the phosphate fully explain the 
strict specificity of RasADH for NADPH over the non-phosphorylated cofactor NADH 
[10]. 
The active site tunnel in SyADH is situated between two loops formed by Gly195-
Val204 and Phe144-Met150, the former in place of helix 6 in RasADH. The 
nicotinamide ring again occupies the base of the tunnel, the lining of which shares 
significant homology with RasADH, with probable proton donor Tyr153 (RasADH-
Tyr150), Ser140 (Ser137), Met150 (His147), and Val141 (Val138), conserved in 
respect of steric bulk, but with three larger hydrophobic residues from RasADH 
replaced by alanine: Ala92 (equivalent to RasADH Ile91) and Ala145 (Leu142) and 
Ala194 (Gln191), suggestive, at least superficially, of a greater active site volume in 
SyADH overall. Additional steric bulk is provided in the active site by Trp191 (Ile188) 
and Phe148 (Leu144). The 2’-ribose phosphate group of NADPH is less constrained in 
SyADH than in RasADH; Arg36 mirrors the location and function of RasADH-Arg38, 
but RasADH-Arg39 is not present and is replaced by an aspartate (Asp37) that points 
away from the phosphate binding site. Ser13 replaces RasADH Gln15 in the other direct 
interaction with phosphate. The side-chain of an additional arginine, Arg40, which is 
not present in RasADH is close to the phosphate in SyADH, but, with both terminal N-
atoms of the side chain at 3.6 Å and 3.8 Å from the phosphate oxygen, too far away to 
suggest a major role in phosphate binding. 
The nicotinamide rings of the NADPH cofactors in each case are presented to the active 
site cavity. The C4 atom of the nicotinamide ring, from which hydride will be delivered 
to the substrate carbonyl, is in each case 4.2 Å (RasADH) or 4.3 Å (SyADH) from the 
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phenolic hydroxyl of the tyrosine proton donor. In SyADH, the region extending from 
the space between the nicotinamide C4 and the phenolic hydroxyl of Tyr153, and out 
into the hydrophobic cavity, contained electron density although no obvious ligands that 
featured in the crystallization conditions could be modelled.   
 
Modelling bulky-bulky ketones in the active sites 
RasADH and SyADH are distinctive in their ability to reduce ketones in which the 
prochiral carbonyl group is bounded on either side by hydrophobic groups, such as  n-
pentyl phenyl ketone 1, which is transformed by each enzyme into the (S)-alcohol with 
excellent enantiomeric excess. With the structures of the enzymes in hand, it was now 
possible to model the structure of 1 into their active sites, in the knowledge that, given 
the known (S)-stereospecificity of the enzymes with this substrate, only the re-face of 
the prochiral ketone would be presented to the C4-nicotinamide atom that delivers 
hydride, and also that the carbonyl group must be situated within H-bonding distance of 
the relevant conserved serines (Ser137 in RasADH and S140 in SyADH) and tyrosine 
proton donors (Tyr150 in RasADH and Tyr153 in SyADH) that are involved in 
catalysis [23]. 1 was modelled into the active sites of RasADH and SyADH using the 
programme AUTODOCK-VINA [24] using a procedure described in the Experimental 
Section. A comparison of these models is shown in Figure 5.  
In the model of SyADH with substrate 1, the hydrophobic tunnel can be described in 
terms of a proximal region nearer the surface of the enzyme, in which the phenyl ring is 
bound, and a distal region towards the enzyme interior, which binds the alkyl chain. The 
re-face of the carbonyl in 1 is positioned against the nicotinamide ring of NADPH, with 
the C=O oxygen at a distance of 2.5 Å and 3.4 Å from the side chains of Ser140 and the 
proton donor Tyr153 respectively. As a consequence, the phenyl ring is accommodated 
in the proximal region of the tunnel, bounded by hydrophobic residues Val141, Ala184, 
Leu201 and Phe148. The pendant n-pentyl group penetrates the distal region of the 
tunnel and is bounded by further hydrophobic residues Trp191, Ile190, Ala92 and 
Met150. In RasADH, the requisite interactions of the carbonyl group with the C4 of 
NADPH are still observed, but the phenyl ring of the substrate is pressed further into the 
active site in relation to the SyADH model complex, as a result of steric repulsion by 
residue Phe205, which is part of the ‘lid’ helix 6.  In the distal region of the 
hydrophobic tunnel, penetration of the n-pentyl chain is prevented by Gln191 and is 
displaced into the region of the active site occupied by Ile188, which would not be 
permitted in SyADH because of the presence of bulky Trp191 (seen behind the 
substrate in Figure 5a). The alkyl chain now makes favourable hydrophobic 
interactions in this position with Phe205 and Ile188 (seen behind the substrate in Figure 
4b). The models suggest that although each accepts 1, SyADH is better suited to 
accommodate the substrate. The models are useful in revealing the hydrophobic 
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characteristics of the active sites that permit binding of hydrophobic substrates but also 
the distinctive substrate ranges of SyADH and RasADH.  The model suggest that while 
the flexible alkyl chain of 1 can be accommodated in the distal region of hydrophobic 
tunnel through contortion in RasADH, less flexible substituents, such as aromatics, 
would not be accommodated. This is supported by substrate specificity studies [10], 
which show that compounds such as benzoin are poor substrates for RasADH. For 
SyADH, however, the larger distal portion of the hydrophobic tunnel may allow for the 
accommodation of such bulky groups. The large capacity of the hydrophobic tunnel of 
SyADH also suggests a basis for its non-selectivity towards smaller prochiral ketones 
such as acetophenone [14] with space available for these substrates to be accommodated 
in such a way that presents the si- or the re-face of the carbonyl group to the NADPH 
hydride at C4 of the cofactor nicotinamide ring. 
 
Conclusion 
The structures of RasADH and SyADH have revealed the structural basis for the 
recognition of bulky-bulky ketones in a hydrophobic tunnel near the surface of the 
enzymes. The structures of enzymes with potential use in biocatalytic applications can 
be valuable in identifying active site determinants of substrate specificity and 
enantioselectivity that may inform rational engineering, or randomised mutagenesis at 
targeted residues, for improved or altered specificity.   
 
Experimental Section 
Gene cloning, expression and protein purification 
The genes encoding RasADH and SyADH were obtained from the laboratory of 
Professor Wolfgang Kroutil, University of Graz, Austria. Each gene was subcloned into 
the pET-YSBLIC-3C vector in York. RasADH was amplified by PCR from the 
template plasmid using the following primers: 5’- 
CCAGGGACCAGCAATGTATCGTCTGCTGAATAAAACCGCAGTTATTACCG -
3’ (Forward) and 5’- 
GAGGAGAAGGCGCGTTATTAAACCTGGGTCAGACCACCATCAACAAACAG -
3’ (Reverse). SyADH was amplified using primers 5’- 
CCAGGGACCAGCAATGACCACCCTGCCGACCGTTCTG -3’ (Forward) and 5’- 
GAGGAGAAGGCGCGTTATTATTATTTTTCAAACTGCGGATGTGACCATGC -
3’ (Reverse). Following agarose gel analysis of the PCR products, the relevant bands 
were eluted from the gels using a PCR Cleanup kit® (Qiagen). The genes were then 
subcloned into the pET-YSBL-LIC-3C vector using previously published techniques 
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[15]. The resultant plasmids were then used to transform E. coli XL1-Blue cells 
(Novagen), yielding colonies which in turn gave plasmids using standard miniprep 
procedures that were sequenced to confirm the identity and sequence of the genes.  
The recombinant vector(s) containing the RasADH and SyADH genes were used to 
transform E. coli BL21 (DE3) cells using 30 	g mL-1 kanamycin as antibiotic marker on 
Luria Bertani (LB) agar. Single colonies from agar plate grown overnight were used to 
inoculate 5 mL cultures of LB broth, which were then grown overnight at 37°C with 
shaking at 180 r.p.m. The starter cultures served as inocula for a 1 L cultures of LB 
broth in which cells were grown until the optical density (OD600) had reached a value of 
0.8. Expression of either RasADH or SyADH were then induced by the addition of 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG). The cultures were then incubated at 
18°C in an orbital shaker at 180 r.p.m. for approximately 18 h. The cells were harvested 
by centrifugation for 15 min at 4225 g in a Sorvall GS3 rotor in a Sorvall RC5B Plus 
centrifuge. At this point, considerations specific to each protein applied and purification 
strategies diverged. 
For RasADH, cell pellets were resuspended in 20 mL of 50 mM Tris-HCl buffer pH 7.5 
containing 500 mM NaCl, 20 mM imidazole, 1 mM CaCl2 and 10% glycerol (v/v) 
(buffer ‘A‘) per 1 L of cell culture. The cell suspensions were then sonicated for 10 x 
45s bursts at 4°C with 30 s intervals. The soluble and insoluble fractions were separated 
by centrifugation for 30 min at 26,892 g in a Sorvall SS34 rotor. The crude cell lysate 
from 1L cell culture was loaded onto a 5 mL HisTrap FF crude column (GE Healthcare), 
which was then washed with buffer ‘A‘) and then the protein eluted with a linear 
gradient of 20-300 mM imidazole. Fractions containing RasADH were combined and 
concentrated using a 10 kDa cut-off Centricon® filter membrane. The concentrated 
RasADH was then loaded onto a pre-equilibrated S75 Superdex™ 16/60 gel filtration 
column, which was then eluted with 120 mL of buffer ‘A‘ without imidazole, using a 
flow rate of 1 ml min-1. Fractions containing pure RasADH, as determined by SDS-
PAGE analysis were combined and stored at 4°C. For SyADH, an equivalent procedure 
was employed using, in place of buffer ‘A‘, a 50 mM Tris-HCl buffer containing 300 
mM NaCl and 20 mM imidazole only (buffer ‘B‘). All subsequent procedures were 
equivalent to the strategy employed for RasADH, with purification performed using Ni-
NTA chromatography followed by gel filtration. In the case of SyADH, prior to 
crystallisation, the histidine tag was cleaved using C3 protease using a procedure 
described previously [15]. 
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Protein Crystallisation 
Crystallization conditions for both enzymes were determined using commercially 
available screens in the sitting-drop format in 96-well plates using 300 nL drops (150 
nL protein plus 150 nL precipitant solution). Positive hits were scaled up in 24 x a mL 
Linbro dished using the hanging-drop method of crystallisation, with crystallisation 
drops containing 1 	L of protein solution and 1 	L of precipitant reservoir. For the apo-
RasADH, the best crystals were obtained in 0.1 M Bis-tris propane pH 7.0 containing 
20% (w/v) PEG 3350 and 0.02 M sodium-potassium phosphate. The protein 
concentration was 24 mg mL-1. For the RasADH NADPH complex, the best crystals 
were obtained in 0.1 M Bis-tris propane pH 8.0, containing 16% (w/v) PEG 3350, 0.2 
M KSCN and 5% (w/v) ethylene glycol. The protein concentration in each case was 24 
mg mL-1. In each case, the crystals were picked and transferred to a solution of the 
mother liquor containing 20% (v/v) ethylene glycol as cryoprotectant and 10 mM 
NADPH, and left for 5 min. The crystals were then flash cooled in liquid nitrogen prior 
to diffraction analysis. 
For the SyADH-NADPH complex, the best initial crystals were obtained in conditions 
containing 0.1 M MES buffer pH 5.5 with 0.3 M sodium acetate and 15% (w/v) PEG 
4K, with a protein concentration of 20 mg mL-1. As with RasADH, crystals were picked 
and transferred to a solution of the mother liquor containing 20% (v/v) ethylene glycol 
as cryoprotectant and 10 mM NADPH, and left for 5 min. The crystals were then flash-
cooled in liquid nitrogen prior to diffraction analysis.  
Crystals were tested for diffraction using a Rigaku Micromax-007HF fitted with Osmic 
multilayer optics and a Marresearch MAR345 imaging plate detector. Those crystals 
that diffracted to greater than 3 Å resolution were retained for full dataset collection at 
the synchrotron. 
 
Data Collection, Structure Solution, Model Building and Refinement of Q1EQE0 
Complete datasets for the apo-RasADH and its NADH complex, and the SyADH 
complex with NADPH were collected on beamlines I04, I02 and I04 respectively, at the 
Diamond Light Source, Didcot, Oxfordshire, U.K. Data were processed and integrated 
using XDS [25] and scaled using SCALA [26] as part of the Xia2 processing system 
[27]. Data collection statistics are given in Table 1. The structure of the apo-RasADH 
was solved using MOLREP [28], using a monomer of structure PDB code 4FGS as a 
search model. The solution contained four molecules in the asymmetric unit, 
representing one tetramer. The structure of the RasADH NADPH complex was then 
solved using the monomer of the apo-RasADH.  The structure of SyADH was solved 
using the programme BALBES [20], which selected a monomer of the PDB code 
structure 3P19 as a model. The solution contained five dimers in the asymmetric unit. 
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All structures were built and refined using iterative cycles of Coot [29] and REFMAC 
[30] employing local NCS restraints. For NADPH complexes of both RasADH and 
SyADH, the omit maps, after building and refinement of the proteins, revealed  residual 
density at the active sites, which could in each case be successfully modelled and 
refined as NADPH. The final structures of apo-RasADH, RasADH (NADPH) and 
SyADH (NADPH) exhibited Rcryst and Rfree values of 15.8/18.8%, 26.8/29.3% and 
23.4/25.1 respectively. The structures were validated using PROCHECK [31]. 
Refinement statistics are presented in Table 1. The Ramachandran plot for apo-
RasADH showed 97.8% of residues to be situated in the most favoured regions, 1.6% in 
additional allowed and 0.5% outlier residues. For the RasADH-NADPH complex, the 
corresponding values were 95.3%, 4.6% and 0.1% respectively. For the SyADH-
NADPH complex, the corresponding values were 99.0% and 1% with no residues in 
outlier regions. Coordinates and structure factors for apo-RasADH RasADH-NADPH 
and SyADH-NADPH have been deposited in the Protein Data Bank with the accession 
codes 4bmn, 4bms and 4bmv respectively. 
 
Docking 
Automated docking was performed using AUTODOCK VINA 1.1.2 [24]. Structures for 
RasADH, SyADH were prepared using AUTODOCK utility scripts. Coordinates for 
substrate 1 were prepared using PRODRG [32]. A monomer model was used for 
RasADH and a dimer model was used for SyADH with the appropriate pdbqt files 
prepared in AUTODOCK Tools. The active site of RasADH and SyADH was contained 
in a grid of 20 x 30 x 20 and 24 x 18 x 14 respectively with 0.375Å spacing, centred 
around the catalytic centre which was generated using AutoGrid in the AUTODOCK 
Tools interface. The number of runs for genetic algorithm was set to 10 and the rest of 
the docking parameters were set to default parameters. The dockings were performed by 
VINA, therefore the posed dockings were below 2Å rmsd. The results generated by 
VINA were visualised in AUTODOCK Tools 1.5.6 where the ligand conformations 
were assessed upon lowest VINA energy, but also the following criteria: The known 
mechanisms of short-chain ADHs [23] and experimentally-determined 
enantioselectivity of both RasAH and SyADH for ketone 1 dictated that only poses in 
which the carbonyl of 1 was observed to make appropriate interactions with the 
phenolic hydroxyl of the catalytic tyrosine residue (Tyr150 or Tyr153 for RasADH or 
SyADH respectively); the conserved active site serine, which hydrogen bonds to the 
substrate carbonyl [23] (Ser137 or Ser140 for RasADH or SyADH respectively) and 
which presented the (re)-face of the carbonyl to the nicotinamide ring of NADPH 
(resulting in the (S)-alcohol product), were considered. 
 
 
  
II     Publications 
 
  

References 
[1] Nakamura K, Yamanaka R, Matsuda T, Harada T (2003) Recent developments in 
asymmetric reduction of ketones with biocatalysts. Tetrahedron: Asymmetr 14:2659-
2681. 
[2] Goldberg K, Schroer K, Lütz S, Liese A (2007) Biocatalytic ketone reduction—
a powerful tool for the production of chiral alcohols—part II: whole-cell reductions. 
Appl Microbiol Biotechnol 76:249-255. 
[3] Schlieben NH, Niefind K, Müller J, Riebel B, Hummel W, Schomburg D (2005) 
Atomic Resolution Structures of R-specific Alcohol Dehydrogenase from Lactobacillus 
brevis Provide the Structural Bases of its Substrate and Cosubstrate Specificity. J Mol 
Biol  349: 801-813. 
[4] Nie Y, Xu Y, Mu XQ, Wang HY, Yang M, Xiao R (2007) Purification, 
Characterization, Gene Cloning, and Expression of a Novel Alcohol Dehydrogenase 
with Anti-Prelog Stereospecificity from Candida parapsilosis. Appl Environ Microbiol 
73: 3759-3764. 
[5] Höllrigl V, Hollmann F, Kleeb A, Buehler K, Schmid, A (2008) TADH, the 
thermostable alcohol dehydrogenase from Thermus sp. ATN1: a versatile new 
biocatalyst for organic synthesis. Appl Microbiol Biotechnol 81:263-273. 
[6] Machielsen R, Uria AR, Kengen SWM, van der Oost J (2006) Production and 
Characterization of a Thermostable Alcohol Dehydrogenase That Belongs to the Aldo-
Keto Reductase Superfamily. Appl Environ Microbiol 72:233-238. 
[7] Karabec M, Lyskowski A, Tauber KC, Steinkellner G, Kroutil W, Grogan G, 
Gruber, K (2010) Structural insights into substrate specificity and solvent tolerance in 
alcohol dehydrogenase ADH-'A' from Rhodococcus ruber DSM 44541. Chem Commun 
46:6314-6316. 
[8] Jakoblinnert A, Mladenov R, Paul A, Sibilla F, Schwaneberg U, Ansorge-
Schumacher MB, de Maria PD (2011) Asymmetric reduction of ketones with 
recombinant E. coli whole cells in neat substrates. Chem Commun 47:12230-12232. 
[9] Lavandera I, Kern A, Ferreira-Silva B, Glieder A, de Wildeman S, Kroutil W 
(2008) Stereoselective Bioreduction of Bulky-Bulky Ketones by a Novel ADH from 
Ralstonia sp. J Org Chem 6003-6005. 
[10] Kulig J, Frese A, Kroutil W, Pohl M, Rother D (2013) Biochemical 
characterization of an alcohol dehydrogenase from Ralstonia sp. Biotechnol Bioeng 
(2013) doi: 10.1002/bit.24857. 
  
II     Publications 
 
  

[11] Kulig J, Simon RC, Rose CA, Husain SM, Häckh M, Lüdeke S, Zeitler K, 
Kroutil W, Pohl M, Rother D (2012) Stereoselective synthesis of bulky 1,2-diols with 
alcohol dehydrogenases. Catal Sci Technol 2:1580-1589. 
[12] Cuetos, A, Rioz-Martínez A, Bisogno FR, Grischek B, Lavandera I, de Gonzalo 
G, Kroutil W, Gotor V (2012) Access to Enantiopure α-Alkyl-β-hydroxy Esters through 
Dynamic Kinetic Resolutions Employing Purified/Overexpressed Alcohol 
Dehydrogenases Adv Synth Catal 354: 1743-1749. 
[13] Lavandera I, Oberdorfer G, Gross J, de Wildeman S, Kroutil, W (2008) 
Stereocomplementary Asymmetric Reduction of Bulky–Bulky Ketones by Biocatalytic 
Hydrogen Transfer. Eur J Org Chem 2008: 2539-2543. 
[14] Lavandera I, Kern A, Resch V, Ferreira-Silva B, Glieder A, Fabian WMF, de 
Wildeman S, Kroutil W (2008) One-Way Biohydrogen Transfer for Oxidation of sec-
Alcohols. Org Lett 10: 2155-2158. 
[15] Atkin KE, Reiss R, Turner NJ, Brzozowski AM, Grogan G (2008) Cloning, 
expression, purification, crystallization and preliminary X-ray diffraction analysis of 
variants of monoamine oxidase from Aspergillus niger. Acta Crystallogr Sect F 64: 
182-185. 
[16] Zhang R, Zhu G, Zhang W, Cao S, Ou X, Li X, Bartlam M, Xu Y, Zhang XC,  
Rao Z (2008) Crystal structure of a carbonyl reductase from Candida parapsilosis with 
anti-Prelog stereospecificity. Protein Sci 17:412-1423. 
[17] Sogabe S, Yoshizumi A, Fukami TA, Shiratori Y, Shimizu S, Takagi H, 
Nakamori  S, Wada M (2003) The Crystal Structure and Stereospecificity of Levodione 
Reductase from Corynebacterium aquaticum M-13. J Biol Chem 278:19387-19395. 
[18] Holm L, Sander C (1996) Mapping the Protein Universe. Science. 273:595-560. 
[19]  Krissinel E, Henrick K (2007) Inference of macromolecular assemblies from 
crystalline state. J Mol Biol 372: 774-797. 
[20] Long F, Vagin AA, Young P, Murshudov GN (2008) BALBES: a Molecular 
Replacement Pipeline. Acta Crystallogr Sect D Biol Crystallogr 64:125-132. 
[21] MacKenzie AK, Kershaw NJ, Hernandez H, Robinson CV, Schofield CJ, 
Andersson I (2007) Clavulanic Acid Dehydrogenase:  Structural and Biochemical 
Analysis of the Final Step in the Biosynthesis of the β-Lactamase Inhibitor Clavulanic 
Acid. Biochemistry 46:1523-1533. 
[22] Supangat S, Seo KH, Choi YK, Park YS, Son D, Han C-D, Lee KH (2006) 
Structure of Chlorobium tepidum Sepiapterin Reductase Complex Reveals the Novel 
  
II     Publications 
 
  

Substrate Binding Mode for Stereospecific Production of l-threo-Tetrahydrobiopterin. J 
Biol Chem 281:2249-2256. 
[23] Filling C, Berndt KD, Benach J, Knapp S, Prozorovski T, Nordling E, 
Ladenstein R, Jörnvall H, Oppermann U (2002) Critical Residues for Structure and 
Catalysis in Short-chain Dehydrogenases/Reductases. J Biol Chem 277:25677-25684. 
[24] Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of 
docking with a new scoring function, efficient optimization and multithreading. J Comp 
Chem 31:455-461. 
[25] Kabsch W (2010) XDS. Acta Crystallogr Sect D Biol Crystallogr 66:125-132. 
[26] Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr Sect D 
Biol Crystallogr 62:72-82. 
[27] Winter G (2010) xia2: an expert system for macromolecular crystallography data 
reduction. J Appl Cryst 3:186-190. 
[28] Vagin A, Teplyakov A (1997) MOLREP: an Automated Program for Molecular 
Replacement. Appl Crystallogr 30:1022-1025. 
[29] Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. 
Acta Crystallogr Sect D Biol Crystallogr 60:2126-2132. 
[30] Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of Macromolecular 
Structures by the Maximum-Likelihood method. Acta Crystallogr Sect D Biol 
Crystallogr 53:240-255. 
[31] Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993) PROCHECK: a 
program to check the stereochemical quality of protein structures. J Appl Crystallogr 
26:283–291. 
[32] Schüttelkopf AW, van Aalten DMF (2004) PRODRG - a tool for high-
throughput crystallography of protein-ligand complexes. Acta Crystallogr Sect D Biol 
Crystallogr 60:1355–1363. 
 
 
Acknowledgements 
This research was supported by a Marie Curie Network for Initial Training fellowships 
to K.K., J.K. and A.F. in the project BIOTRAINS (FP7-PEOPLE-ITN-2008-238531). 
We would also like to thank Prof. Wolfgang Kroutil of the University of Graz for genes 
encoding both RasADH and SyADH. 
  
II     Publications 
 
  

Table 1. Data Collection and Refinement Statistics for RasADH (apo- and in complex 
with NADPH) and SyADH in complex with NADPH. Numbers in brackets refer to data 
for highest resolution shells. 
 RasADH (apo) RasADH (NADPH 
complex) 
SyADH (NADPH 
complex) 
Beamline Diamond I02 Diamond I04 Diamond I02 
Wavelength (Å) 0.97950 0.97950 0.97949 
Resolution (Å) 60.86-1.52 (1.57-1.52) 74.54-2.89 (2.93-2.89) 139.0 - 2.5 (2.56-2.50) 
Space Group C21 C21 P21 
Unit cell (Å) a = 136.5; b = 52.5; c = 
151.5;  = 
 = 90.0;  = 
116.6 
a = 192.3; b = 135.6; c = 
93.6;  = 
 = 90.0;  = 
100.1 
a = 144.9; b = 86.8; c = 
155.6;  = 
 = 90.0;  = 
106.4 
No. of molecules in 
the asymmetric unit 
4 6 10 
Unique reflections 149646 (45160) 52465 (3880) 133601 (10900) 
Completeness (%) 97.7 (96.8) 99.2 (98.8) 99.7 (99.8) 
Rmerge (%) 0.03 (0.25) 0.18 (0.73) 0.14 (0.54) 
Rp.i.m. 0.03 (0.23) 0.16 (0.64) 0.12 (0.46) 
Multiplicity 3.3 (3.5) 4.2 (4.2) 4.2 (4.3) 
<I/(I)> 15.6 (4.9) 7.4 (2.0) 8.2 (3.0) 
CC1/2 1.00 (0.95) 0.98 (0.74) 0.99 (0.82) 
Overall B factor from 
Wilson plot (Å2) 
24 41 43 
Rcryst/ Rfree (%) 15.8/18.8 26.8/29.3 23.4/25.1 
No. protein atoms 6942 11081 18948 
No. water molecules 846 37 290 
r.m.s.d 1-2 bonds (Å) 0.02 0.01 0.01 
r.m.s.d 1-3 angles (o) 1.69 1.60 1.60 
Avge  main chain B 
(Å2) 
20 35 35 
Avge  side chain B 
(Å2) 
23 36 37 
Avge  water B (Å2) 33 14 20 
Avge  ligand B (Å2) - 32 30 
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Figures 
 
Figure 1. Representative asymmetric reductions of bulky-bulky ketones catalysed by 
alcohol dehydrogenases from Ralstonia sp. DSM 6428 (RasADH) and Sphingobium 
yanoikuyae DSM 6900  (SyADH). 
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Figure 2. Structure of RasADH. a: The asymmetric unit of the apo-enzyme contained 
four monomers A-D that constituted one tetramer, which is shown in ribbon format and 
coloured by chain. b: Monomer of RasADH apoenzyme (green ribbon) superimposed 
with monomer of RasADH holoenzyme (coral ribbon) in complex with NADPH. The 
rmsd for the two structures over 201 C-alphas was 0.42 Å. The monomer(s) display the 
typical Rossmann fold, with a central -sheet surrounded by six helices, four of which, 
3, 4, 5 and 6. Helix 6, which was absent in the apoenzyme structure, appears to 
act as a lid to the active site, closing over the NADPH molecule when cofactor is bound.  
The N and C termini of the apo enzyme monomer are also indicated. The cofactor 
NADPH is shown in cylinder format with carbon atoms shown in grey. 
 
Figure 3. Structure of SyADH. a: The asymmetric unit contains ten monomers that 
constitute five dimers shown in ribbon format and coloured by chain. b: Each dimer 
consist of two monomers, coloured green and coral, each of which exhibits the 
Rossmann ()8 fold, with eight helices (numbered 1-4 and 8 for the coral 
monomer; 5 is obscured)  forming the central bundle and a ninth helix 9 that 
associates closely with the neighbouring monomer.  The N and C termini of the coral 
monomer are also indicated.  The cofactor NADPH is shown in cylinder format with 
carbon atoms shown in grey. 
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Figure 4. Superimposition of active sites of RasADH and SyADH illustrating side-
chain components of the hydrophobic tunnel in both active sites. RasADH is shown in 
ribbon format in coral with side chains projecting from the backbone and the 
nicotinamide ring of NADPH (centre) shown (carbon atoms in coral). SyADH is shown 
in light blue ribbons with NADPH and side chains (carbon atoms in light blue). 
 
Figure 5. Ketone 1 modelled into the active site of a) SyADH and b) RasADH using 
the programme AUTODOCK VINA [24]. In a), the carbon atoms of the side chains of 
SyADH are shown in light blue in cylinder format; 1 is shown in ball-and-stick format 
with the carbon atoms in black. In b), the carbon atoms of the side chains of RasADH 
are shown in coral in cylinder format; 1 is again shown in ball-and-stick format with the 
carbon atoms in black. 
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3.1 Overview of publications 
Results obtained in this doctoral thesis were predominantly obtained at the IBG-1: 
Biotechnology at Forschungszentrum Jülich GmbH. Additional work packages 
concerning cloning, purification and crystallisation of His-tagged RADH were 
performed at the Department of Chemistry (York Structure Biology Laboratory), 
University of York, UK under supervision of Dr. Gideon Grogan. The relation of 
all four publications is shown in Figure 18.  
 
Figure 18. Relation of publications on results obtained in this thesis. 
PUBLICATION I describes the investigation of the substrate range of seven alcohol 
dehydrogenases and one carbonyl reductase towards various aldehydes, ketones 
and especially α-hydroxy ketones. Stereoselectivities of the three most active 
alcohol dehydrogenases towards α-hydroxy ketones was investigated in more detail. 
Additionally, an extended substrate range investigation of the most promising 
alcohol dehydrogenase, RADH from Ralstonia sp., is described. 
PUBLICATION II reports the full biochemical characterisation of the alcohol 
dehydrogenase from Ralstonia sp. as the most active enzyme towards various 
substituted α-hydroxy ketones determined so far. In this publication the effect of 
Ca2+ ions for stabilisation of RADH is discussed and the possibility of a trimeric 
quaternary structure is considered. Moreover, pH- and temperature dependent 
activities (for oxidation and reduction) and stabilities were investigated. 
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Subsequently, under optimal conditions the substrate range (alcohols, aldehydes 
and ketones) was studied. Kinetic parameters were determined for the selected 
substrates relevant for the 2-step enzymatic cascade reactions. 
PUBLICATION III describes the evaluation and optimisation of suitable cofactor 
regeneration systems for a model cascade reaction using BAL as a ThDP-
dependent lyase for the carboligation step and RADH for the oxidoreduction step. 
The publication is based upon the two previous publications, where substrate 
ranges, stereoselectivities (Publication I) and kinetic data (Publication II) were 
determined. 
PUBLICATION IV reports the structure determination and refinement to resolutions 
of 1.5 Å and 2.9 Å, respectively, of the apo-enzyme and the holo-enzyme in complex 
with NADPH. In addition, the preference of RADH for bulky-bulky substrates and 
the specificity for NADPH could be explained. 
 
3.2 Alcohol dehydrogenases as versatile catalysts 
In this thesis seven alcohol dehydrogenases (ADHT, FADH, HLADH, LBADH, 
RADH, SADH and TADH) and the carbonyl reductase (CPCR) were investigated 
with respect to their substrate specificity focusing on the reduction of α-hydroxy 
ketones. These enzymes were chosen, since it was expected from literature data that 
they might be able to reduce α-hydroxy ketones that are significantly larger 
compared to small aliphatic alcohols, which are the predominant natural substrates 
for ADHs. 
The screening was conducted employing crude cell extracts containing 
overexpressed enzyme. Purification at that stage was omitted, since it is a time-
consuming process and not essential for a first trial. Implementation of crude cell 
extracts provided rapid insight into the substrate range of these all enzymes (Table 7, 
Publication I). For investigation of the substrate range a fast spectrophotometrical 
enzyme assay was applied, where the reduction or oxidation of respective substrates 
was monitored at 340 nm following the depletion or increase of NAD(P)H, 
respectively (Figure 19). 
According to the obtained results three alcohol dehydrogenases were selected as 
most promising enzymes for the reduction of α-hydroxy ketones. Among them are 
the recombinant alcohol dehydrogenases from Thermoanaerobacter sp. (ADHT), 
Lactobacillus brevis (LBADH), and Ralstonia sp. (RADH). 
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Figure 19. Absorption spectrum of oxidised (NAD(P)+) and reduced (NAD(P)H) cofactor. Oxidised 
and reduced forms of the cofactor absorb ultraviolet light at about 260 nm, which is 
caused by the adenine moiety in the molecules. The extinction coefficient of NAD(P)+ is 
ℇ260 nm = 16 900 M
–1 cm–1, The reduced form of the cofactor (NADPH) shows an 
additional absorbtion maximum at 340 nm due to the reduced nicontinamide ring  
ℇ340 nm = 16 900 M
–1 cm–1). 
The investigation of substrate ranges (Table 7) demonstrated that LBADH reduces 
especially aliphatic α-hydroxy ketones such as acetoin (5), its derivative (6), and 
propioin (7) with high specific activities. A similar tendency was found for ADHT, 
where as well highest activities were determined for aliphatic α-hydroxy ketones (5-
7). A different behaviour was observed for RADH, where a clear preference for the 
reduction of mixed araliphatic α-hydroxy ketones was found. For instance,  
α-hydroxy ketones of central interest such as 2-hydroxy-1-phenylpropan-1-one (2-
HPP, 9) and 1-hydroxy-1-phenylpropan-2-one (PAC, 12) were reduced with 
extremely high initial rate activities in comparison to tested in this thesis ADHT 
and LBADH for the reduction of 2-HPP (9, see Table 7 and Publication I). A 
possible background reaction was excluded with an E. coli empty vector control. 
It has to be pointed out that almost all tested α-hydroxy ketones were well reduced 
by ADHT, LBADH, and RADH. Highest specific activities were determined with 
ADHT and LBADH for acetoin (5, 18 U mg–1 and 128 U mg–1, respectively) and 
with RADH for (R)-2-HPP (240 U mg–1). Low activities toward benzoin (13) and 
its derivative α-pyridoin (14) might be caused by low solubility of these compounds 
in aqueous media. 
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3.3 Stereoselectivity of ADHs 
All α-hydroxy ketones were reduced with high stereoselectivity. Predominantly 
only one stereoisomer occurred (de > 99%) starting from a chiral substrate 
(ee > 99%) (Table 8). 
From investigations of the 2-HPP racemate the diastereomeric ratio of the resulting 
diastereoisomers provided information about enzyme selectivity and enzyme 
kinetics towards both enantiomers. For instance, reduction of rac-2-HPP (9) 
catalysed by ADHT showed clear preference for the reduction of (R)-2-HPP (dr 
syn/anti 23.6:1) under the tested conditions. A similar tendency (for the favoured 
reduction of (R)-2-HPP) was found for isolated RADH, where reduction of (R)-2-
HPP proceeds 4-times faster (dr syn/anti 4:1) than the reduction of the opposite 
enantiomer (Table 8). This result goes in line with kinetic data, which are discussed 
in chapter 3.4.6. In case of LBADH the same amounts of syn- and anti-diol were 
formed (dr syn/anti 1:1) when rac-2-HPP was reduced. This outcome shows that 
LBADH shows no preference for one enantiomer of 2-HPP. 
Interestingly, in all investigated cases reduction of the two isomeric compounds (R)-
2-HPP (9) and (R)-PAC (12), which differ only in the position of chiral centre, 
resulted in inversed stereoselectivities of the product. (R)-PAC (12) was reduced by 
ADHT and RADH (S)-selectively yielding the anti-product, whereas reduction of 
(R)-2-HPP (9) proceeded (R)-selectively to the syn-product. The opposite effect was 
observed in case of LBADH, where reduction of (R)-PAC (12) and (R)-2-HPP (9) 
revealed the syn- and anti-product, respectively. 
Furthermore, LBADH follows the anti-Prelog rule yielding diastereo-
complementary products in comparison to products gained by catalysis with 
ADHT and RADH (Table 8). Therefore a broad range of highly selective products 
can be accessed by an appropriate combination of these biocatalysts. 
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Figure 20. Syntheses of chiral diols using enzymatic toolboxes: ThDP-dependent enzymes (centre) 
for carboligation of aldehydes to α-hydroxy ketones (white ring), and subsequent 
reduction to 1,2-diols using different oxidoreductases (blue ring). R1 = phenyl, R2 = 
methyl, PDC = pyruvate decarboxylase, BFD = benzoylformate decarboxylase, BAL = 
benzaldehyde lyase, KdcA = -keto acid decarboxylase, ADHT = Thermoanaerobacter sp. 
alcohol dehydrogenase, CPCR = Candida parapsilosis carbonyl reductase, FADH = 
Flavobacterium frigidimaris alcohol dehydrogenase, HLADH = horse liver alcohol 
dehydrogenase, LBADH = Lactobacillus brevis alcohol dehydrogenase, RADH = Ralstonia 
sp. alcohol dehydrogenase, SADH = Sphingobium yanoikuyae alcohol dehydrogenase, 
TADH = Thermus sp. ATN1 alcohol dehydrogenase. 
Depending on the combination of the enzymes all four stereoisomers of  
1-phenylpropane-1,2-diol could be obtained (Table 8). All of these reductions were 
catalysed with very high stereoselectivity (ee > 99%, de > 99%). It has to be 
mentioned that during reduction of the keto function, the chiral information of the 
hydroxy function is maintained. Therefore no loss of stereoselectivity of the educt 
was observed under the tested conditions. 
Conclusively the 2-step enzymatic approach for the synthesis of 1,2-diols from 
inexpensive aldehydes is a useful and competitive method to gain highly valuable 
chiral precursors (see Table 8), what is not the case with chemical methods. 
Furthermore, it eliminates toxic catalysts, which are implemented in the chemical 
syntheses of these compounds (e.g. OsO4, NaBH4, LiAlH4) (see chapter 1.11.1). 
Therefore the biocatalytic synthetic cascade approach of 1,2-diols is much 
“greener”. 
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The stereoselective 2-step enzymatic synthesis allows building up a platform of 
diversely substituted 1,2-diols by the combination of two enzymatic toolboxes. 
Depending on the combination of ThDP-dependent enzyme and oxidoreductase 
the selective production of one stereoisomer out of a number of theoretically 
possible products is now achievable (Figure 20) due to the high chemo- and 
stereoselectivity of each enzyme. 
 
3.4 Biochemical characterisation of ADH from Ralstonia sp. 
In the group of Kroutil the alcohol dehydrogenase from Ralstonia sp. (RADH) was 
found to be an excellent catalyst for the reduction of sterically hindered compounds 
(e.g. ketones) (Lavandera et al. 2008a; Lavandera et al. 2008c). They investigated 
the great potential towards large aromatic substrates with crude cell extract from 
lyophilised E. coli-cells, but never tested activity towards α-hydroxy ketones. 
Initial screening of the RADHs substrate scope described in Publication I shows the 
high potential of alcohol dehydrogenases, especially from Ralstonia sp., for the 
reduction of the prochiral carbonyl group of α-hydroxy ketones. Motivated by these 
results RADH was biochemically characterised in detail.  
 
3.4.1   Purification and storage stability 
The radh gene was gratefully obtained from Prof. Dr. W. Kroutil (University of 
Graz, Austria) and cloned into the high copy plasmid (pET-22b). E. coli BL21(DE3) 
was transformed with this vector, cultivated and RADH was overexpressed after 
induction (Publication I). 
E. coli cells containing overexpressed RADH were disrupted and purification of the 
enzyme was carried out in three chromatographic steps encompassing a preliminary 
desalting of the crude cell extract by size exclusion chromatography (SEC) (1st step), 
anion exchange chromatography (2nd step), and a final desalting step of the purified 
enzyme (3rd step) using SEC in order to remove salt from the second purification 
step (see Publication II). RADH was obtained with purity of about 90% according 
to SDS-PAGE electrophoresis. 
The isolated enzyme can be stored at –20 °C without any loss of activity over  
80 days as (I) a frozen protein stock solution in desalting buffer (TEA-HCl, 10 mM, 
pH 7.5) or (II) a glycerine stock (50 vol%) in desalting buffer (TEA-HCl, 10 mM, 
pH 7.5) (Publication II). Lyophilisation of the enzyme can be also used to 
concentrate the liquid protein. The lyophilised protein is stable for at least 20 days 
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stored at –20 °C, but requires a relatively long reactivation time after re-dissolving 
the lyophilised protein in buffer (Publication II). 
 
3.4.2   Effect of salts  
Purification of RADH gave first insights into the enzyme stability. The purified 
enzyme was relatively unstable at room temperature (half-life: ~6 hours), which 
initiated further studies concerning essential metal-ions or other additives that 
might be crucial for enzyme stability. 
The stability issue of ADHs is known from a number of examples, where enzyme 
stability and/or activity are improved in the presence of metal ions. Metal ions in 
the active centre of alcohol dehydrogenases may act as catalytic ions. Besides, 
metal ions can have a structural function, which is known for several alcohol 
dehydrogenases for example from horse liver (HLADH) or Lactobacillus brevis 
(LBADH). HLADH and LBADH lose their activity and stability in the absence of 
zinc and magnesium ions, respectively (Maret et al. 1979; Niefind et al. 2003; 
Niefind et al. 2000). 
Examination of the influence of different metal chlorides on the activity of RADH 
revealed no activators under initial rate conditions. However, several metal ions 
displayed inhibitory effects. Among them were cobalt-, copper-, zinc-, manganese 
and nickel chloride with zinc chloride having the strongest impact (reduction to 
39% of initial rate activity). Copper- and manganese chloride reduced the initial 
activity rate to 75%, whereas the activity in the presence of cobalt- and nickel 
chloride dropped moderately to 85-86% (Publication II). 
Other tested chlorides (CaCl2, KCl, NaCl and MgCl2) did not affect the enzyme 
activity and therefore were investigated as potential enzyme stabilisers. The time-
dependent activity measurements of RADH in the presence of these salts (1 mM) 
resulted in the finding that the enzyme is stabilised by Ca2+ ions. After 2 hours 
RADH retained 97.8% of the initial activity in comparison to the buffer control 
(without any metal chlorides) where only 79.6% of initial activity was retained 
(Publication II). Up to now only one pyrroloquinoline quinone (PQQ)-dependent 
alcohol dehydrogenase was found as an enzyme, which is stabilised and activated 
by Ca2+ ions (Zhao et al. 2000). 
Unfortunately, Ca2+ ions could not be detected in the crystal structure of RADH 
(Publication IV). Thus, the role of Ca2+ for enzyme stability remains unclear.  
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3.4.3   Determination of the native molecular weight of RADH 
According to the calculated molecular weight of the RADH (ExPASy) based on the 
amino acid sequence, a single subunit of the enzyme has a molecular weight of 
26.7 kDa. The estimated molecular weight of RADH by size exclusion 
chromatography (SEC) is 75 kDa, suggesting a trimeric structure of RADH. 
Trimeric enzymes are not common in nature. Up to now only several formaldehyde 
dehydrogenases were reported as trimeric enzymes (Eggeling and Sahm 1985; van 
Ophem et al. 1992). To the best of my knowledge, this would be the first trimeric 
NADPH-dependent alcohol dehydrogenase stabilised by Ca2+ ions. 
Finally the crystal structure of the enzyme demonstrated a tetrameric structure of 
the enzyme. The structure seems to be more or less globular, so the results obtained 
with SEC could not be explained by structural analysis (Publication IV). 
 
3.4.4   pH- and temperature optima 
RADH indicates a broad pH-optimum for reduction (pH 6.0-9.5) and a sharp 
optimum for oxidation (pH 10.0-11.5) (Figure 21). 
 
Figure 21. pH optima for the reduction of benzaldehyde (black) and the oxidation of cyclohexanone 
(blue), respectively. Symbols: ○ – citrate-phosphate buffer (50 mM + CaCl2, 0.8 mM, pH 
5-7), ￭ – TEA-HCl buffer (50 mM + CaCl2, 0.8 mM, pH 7-8), △ – TRIS-HCl buffer 
(50 mM + CaCl2, 0.8 mM, pH 7-8.5), ● – glycine-NaOH buffer (50 mM + CaCl2, 
0.8 mM, pH 8.5-12) (Publication II). 
Furthermore, pH-dependent stability investigation proved the enzyme to be stable 
(half-lives: 60-70 h, 25 °C) in a pH range from 5.5 to 8.0, thus including the pH 
range, where reduction is favoured. 
According to the obtained results, application of RADH for oxidation and/or 
reduction requires careful selection of the pH value, under which either reduction 
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or oxidation, or both are catalysed simultaneously (e.g. if enzymatic cofactor 
regeneration is implemented, see chapter 3.6.1.1). 
The temperature optimum of RADH showed highest initial rate activity at 45 °C. 
In contrast, highest stability was found between 8-15 °C (half-life: ~130 h). 
In order to implement RADH for biocatalysis, a compromise of high enzyme 
activity and stability has to be found to achieve highest enzyme performance. In 
order to allow substrate-coupled cofactor regeneration a pH range between pH 8 
and pH 9 should be chosen to gain high enzyme activity for reduction and 
oxidation step, and reasonable stability for the reaction time as well. 
Conclusively, the pH- and temperature-dependent activity and stability profile of 
RADH allows the application of the enzyme under mild reaction conditions. 
 
3.4.5   Substrate range for oxidation and reduction 
The extended biochemical characterisation of RADH revealed its high potential for 
reductions of the prochiral keto group of α-hydroxy ketones (Publication I). It has 
to be pointed out that kinetic parameters for oxidation and reduction of the 
majority of investigated compounds were not determined and therefore activities 
cannot be compared in terms of maximal velocities. Maximal velocities can vary 
significantly at different substrate concentrations due to the respective KM-values or 
potential substrate sur-plus inhibition. 
Nevertheless, from investigation of the substrate range of RADH it became obvious 
that the enzyme reduces aldehydes (up to 23.3 U mg–1), ketones (up to 12.6 U mg–1) 
(Publication II) and especially α-hydroxy ketones (up to 362 U mg–1) with high 
velocities (Publication I). Under these conditions (pH 7.5), oxidation is less 
favoured. Here maximal rates were obtained for the cyclohexanol oxidation (up to 
18.8 U mg–1) (Publication II). Investigation of the substrate scope demonstrated that 
RADH accepts cyclic and aromatic compounds best, especially α-hydroxy ketones 
like 2-HPP derivatives, where the pro-chiral keto group is located next to a methyl 
group (for details see Publication I and II). 
 
3.4.6   Steady-state kinetic parameters 
In order to find optimal conditions for multi-enzymatic synthetic cascade reaction, 
it is not only important to determine appropriate substrate concentrations for 
maximal reaction velocities, but also the concentrations of cofactor have to be 
properly adjusted. In addition, determination of kinetic parameters allows 
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appropriate process design in order to avoid potential limitations by substrate, 
cofactor, and product inhibitions. 
Since the aim of this work is a 2-step enzymatic synthesis combining a carboligation 
and a oxidoreduction step, all for this process relevant kinetic data are summarised 
in Table 9. It must be noted that kinetic studies with acetaldehyde are missing due 
to the impossibility to determine acetaldehyde precisely by instrumental analysis. 
Table 9. Selected kinetic parameters of RADH relevant for the synthetic enzymatic 2-step cascade 
reaction towards 1,2-diols starting from benzaldehyde and acetaldehyde (Publication II). 
Entry 
Substrate 
[mM] 
Cofactor 
[mM] 
Vmax 
[U mg–1] 
KM 
[mM] 
Ki 
[mM] 
Sopt  
[mM] 
Vopt  
[U mg–1] 
1 Benzyl alcohol 
[0–150] 
NADP+  
[0.8] 
0.3±0.0 12.3±2.7 – – – 
2 Benzaldehyde 
[15] 
NADPH  
[0–0.2] 
5.6±0.1 0.005±0.000 – – – 
3 Benzaldehyde  
[0–50] 
NADPH 
[0.2] 
12.6±0.3 15.6±0.9 – – – 
4 (R)-2-HPP 
[0–15] 
NADPH 
[0.2] 
486.8±52.2 1.6±0.4 16.4 5.1 299.6±32.1 
5 (S)-2-HPP 
[0–20] 
NADPH 
[0.2] 
23.1±0.4 3.6±0.2 – – – 
Kinetic parameters determined for the reduction of (R)- and (S)-2-HPP revealed a 
significant difference of maximal velocities and affinities of RADH for these 
compounds (Publication II). Initial rate activities for the reduction of (R)-2-HPP 
(10 mM) showed extremely high activity of 362.6±1.6 U mg–1, whereas the opposite 
enantiomer, (S)-2-HPP (10 mM) was reduced 21-fold slower (17.1±0.3 U mg–1) (see 
Table 4, Publication I). Kinetic data go in line with previous studies of the substrate 
range (Table 7). However, the high calculated specific activity of  
486.8±52.3 U mg–1 for (R)-2-HPP cannot be reached because of substrate surplus 
inhibition, and therefore Vopt for the reduction was determined as  
299.6±32.1 U mg–1. In contrast to (R)-2-HPP, the (S)-enantiomer did not show  
sur-plus inhibition. Further investigations showed no product inhibition (up to 
> 85 mM of (1R,2R)-diol) in case of (R)-2-HPP (data not shown). Furthermore, 
kinetic studies indicated differences of the enzyme affinity towards (R)- and (S)-2-
HPP, where for the (R)-enantiomer the KM-value is 2.2-fold lower than for the 
opposite enantiomer Table 9). 
Additionally, the data in Table 9 clearly demonstrate that RADH prefers (R)-2-HPP 
over benzaldehyde with respect to maximal velocity, where the velocity for 
benzaldehyde was found to be 23.8-fold lower compared to (R)-2-HPP. This goes in 
line with a 10-fold lower affinity for benzaldehyde compared to (R)-2-HPP, as can 
be deduced from the KM-values. Due to these differences in kinetic parameters 
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RADH the enzyme can principally be applied in one pot together with substrates 
for the carboligation step (Figure 22). 
 
Figure 22. 2-Step enzymatic synthesis of chiral (1R,2R)-1-phenylpropane-1,2-diol by combining a 
carboligation step catalysed by the ThDP-dependent enzyme BAL and a oxidoreduction 
step catalysed by RADH including a cofactor regeneration system. 
Determination of kinetic parameters underlines the high catalytic potential of 
RADH, especially for the reduction of α-hydroxy ketones (Publication I and II). 
These studies show the high significance of efficient reaction engineering and 
adjustment of proper reaction parameters. 
 
3.4.7  Activity in organic solvents 
One key drawback of biocatalysis for industrial applications is solubility limitation 
of organic substrates in aqueous media. This can be circumvented by 
implementation of organic solvents for enzyme-catalysed syntheses. 
 
 
Figure 23. Influence of water-miscible organic solvents (5 vol%) on the initial rate activity of RADH. 
Initial rate activity was measured towards benzaldehyde (10 mM) reduction following 
the consumption of NADPH (0.2 mM) at 340 nm at 30 °C in TEA-HCl buffer (50 mM), 
pH 7.5 supplemented with 5 vol% of the respective organic solvent. DMF = 
dimethylformamide, DMSO = dimethyl sulfoxide, MeCN = acetonitrile, EA = ethyl 
acetate, THF = tetrahydrofuran, MTHF = 2-methyltetrahydrofuran. A relative activity of 
100% corresponds to 3.4 U mg–1 measured for the reduction of benzaldehyde under 
standard conditions.  
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But since organic solvents can influence enzyme activity negatively, the influence of 
various water-miscible organic solvents on the initial rate activity of RADH was 
studied. The results demonstrated that RADH lost activity in the presence of all 
tested organic solvents. Almost complete depletion of initial rate activity of RADH 
for the reduction of benzaldehyde is caused by ethyl acetate (7% residual activity), 
2-methyltetrahydrofuran (8% residual activity), tetrahydrofuran (14% residual 
activity) and 1,4-dioxane (21% residual activity). DMSO, acetonitrile and DMF 
reduce activity also significantly, yielding residual activities of 28-43% (Figure 23). 
The results indicate the limitation of water-miscible organic solvent addition in 
RADH catalysed syntheses in buffered systems. 
 
3.5 Preparations to crystallise RADH 
In order to allow crystallisation of RADH (Publication IV) the coding gene had to 
be cloned into a vector that allows expression of a hexahistidine-tagged enzyme for 
optimal purification. Further, an appropriate purification protocol had to be 
developed. 
 
3.5.1   Cloning RADH into a vector with cleavable tag 
In order to gain highly pure RADH for crystallisation a cleavable His-tag was 
introduced into the enzyme sequence. This N-terminal His6-tag could be cleaved of 
by a protease (HRV 3C), if crystallisation with His-tag fails.  
Cloning of the radh gene was conducted using a ligation independent cloning (LIC-
cloning) method (Figure 24). LIC-cloning is a form of molecular cloning that is 
conducted without the use of restriction endonucleases or DNA ligases. This 
cloning strategy reduces the risk of cleavage of the insert by the restriction enzymes. 
  
3.5.2   Expression and purification of His-RADH 
The obtained fusion protein (His-RADH) was very good expressed in the E. coli T7 
expression system as a soluble protein (induction with 1 mM IPTG final 
concentration, overnight overexpression at 16 °C) (Figure 25).  
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Figure 24. Principles of ligation independent cloning (LIC-cloning) of PCR products. For cloning 
LIC-based primers (FOR and REV primers) are implemented, which consist of vector- 
and desired gene-based sequences. For this purpose vector pET-YSBLIC3C containing an 
N-terminal cleavable His6-tag was implemented (Fogg and Wilkinson 2008). The vector 
is based on pET-28a (KanR), where the thrombin cleavage site was changed to a HRV 3C 
protease (3C protease human rhinovirus type 14) site. HRV 3C protease cleaves the 
sequence: LEVLFQ/GP. After cleavage three additional N-terminal amino acids (GPA) 
remain. The LIC site is introduced between the NcoI and NdeI restriction cleavage sites in 
the modified pET-28a vector. In the multiple cloning site all pET-28a restriction sites are 
intact. 
His-RADH was subsequently purified in three chromatographic steps 
encompassing immobilised metal affinity chromatography (IMAC) and two 
desalting steps (for more details see Protocol, Appendix, paragraph 4.9). Set-up of 
the purification protocol revealed solubility limitations caused by the N-terminal 
His-tag. As His-RADH strongly binds to the chromatography matrix, elution 
required high concentrations of imidazole (up to 300 mM). For elution a flat 
imidazole gradient was used (50-300 mM imidazole, 20 column volumes 
(=100 mL), flow rate: 1 mL min–1, 100 min), since a step gradient causes rapid 
protein precipitation already on the Ni-NTA column. The solubility problem of the 
fusion protein on the Ni-NTA column was solved by several factors. Convenient 
purification without enzyme precipitation could finally be achieved when glycerol 
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(10 vol%) and NaCl (500 mM) were added to every purification step (see Appendix, 
paragraph 4.9). Furthermore, imidazole should not be removed by SEC after 
IMAC; dialysis gives much better results (see Appendix, paragraph 4.9). In order to 
keep the enzyme in soluble form for crystallisation trials the purified fusion protein 
should be stored in the following storage buffer: TRIS-HCl (50 mM) supplemented 
with CaCl2 (1 mM), glycerol (10 vol%) and NaCl (500 mM). 
 
Figure 25. SDS-PAGE electrophoresis of His-RADH purification employing immobilised metal ion 
affinity chromatography (IMAC). A: Lane: 1 – protein ladder, low range (Bio-Rad), 2 – 
crude cell extract, 3 – flow through, 4 – wash 1, 5 – wash 2, 6 – fraction B10, 7 – fraction 
B8, 8 – fraction B6, 9 – fraction C5, 10 – fraction C7, 11 – fraction C9, 12 – fraction C11, 
13 – fraction D12, 14 – fraction D10, 15 – fraction D8. B: Lane: 1 – protein ladder, low 
range (Bio-Rad), 2 – fraction D6, 3 – fraction D4, 4 – fraction D2, 5 – fraction E1, 6 – 
fraction E3, 7 – fraction E5, 8 – fraction E7, 9 – fraction E9, 10 – fraction E11, 11 – 
fraction F12, 12 – fraction F10. Collected fractions – 2 mL each. 
Further investigation of solubility limitation of His-RADH showed that the enzyme 
starts to precipitate at concentrations > 5 mg mL–1 (spectrophotometric 
measurement of protein concentration at 280 nm, measurement based on 
Eppendorf Biophotometer) in storage buffer.  
Besides these solubility issues, the enzyme was obtained with very high purity 
(> 99%) according to SDS-PAGE electrophoresis (Figure 25). 
 
3.5.3   Crystallisation and structure analysis of RADH 
Subsequently, appropriate crystallisation conditions for His-RADH were 
investigated. There were a number of conditions, under which rod crystals occurred. 
Some examples are presented in Figure 26.  
 
 137 
III     Discussion 
 
  
 
 
       
Figure 26. His-RADH crystals. Shown crystals were obtained under following conditions: apo-
RADH: 0.1 M Bis-TRIS propane, pH 7.0 containing 20% (w/v) PEG 3350 and 0.02 M 
sodium-potassium phosphate; holo-RADH: 0.1 M Bis-TRIS propane, pH 8.0 containing 
16% (w/v) PEG 3350, 0.2 M KSCN and 5% (w/v) ethylene glycol. For crystallisation 
24 mg mL–1 of purified His-RADH was used.  
The crystal structure of RADH with NADPH (holo-RADH) and without cofactor 
(apo-RADH) was solved to a resolution of 1.5 Å and 2.9 Å, respectively. 
The structure of RADH was solved by molecular replacement employing a 
monomer of a “probable dehydrogenase protein” from Rhizobium etli CFN42 (55% 
sequence identity with RADH; pdb code: 4FGS) as a model. Structure analysis 
revealed the presence of four monomers A-D (Figure 27A) in the asymmetric unit, 
which form a tetramer (Publication IV). 
A. 
 
B. 
 
Figure 27. Structure of RADH. A. The asymmetric unit of the apo-enzyme contains four monomers 
(A-D) that constitute one tetramer. B. Monomer of apo-RADH (green ribbon) 
superimposed with holo-RADH (coral ribbon). The monomer shows the typical 
Rossmann fold, with a central β-sheet surrounded by six helices. Helix α6 which was 
absent in the apo-RADH appears in holo-RADH and acts as a lid to the active site closing 
molecule  over the NADPH, when cofactor is bound (Publication IV). 
Comparative structural analysis of apo-RADH and holo-RADH indicated that most 
of the electron density of the α6 helix was missing in the apo-RADH while the helix 
A. B. 
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was present in holo-RADH. This observation suggests that the helix appears upon 
NADPH-binding and acts as a lid for the active site, closing over the cofactor in the 
holo-form of the enzyme. 
The enzyme has a large hydrophobic active site tunnel, which is formed at the top 
of the central β-sheet of the Rossmann fold and is partially covered by the α6 helix 
in the holo-enzyme (Figure 27B). The Rossmann fold is a common structural motif 
found in proteins that bind nucleotides, e.g. cofactors. The fold consist of two 
repeats forming a β-α-β-α-β motif (Rossmann et al. 1974). 
The strong preference of NADPH over NADH is controlled by interactions of two 
arginine residues (Arg38 and Arg39) and one residue of asparagine (Asn15) with 
the phosphate group in NADPH.  
A. 
 
B. 
 
 
Figure 28. A. Reduction of n-pentyl phenyl ketone to the respective (S)-alcohol using RADH.  
B. n-Pentyl phenyl ketone modelled into the active site of RADH using the programme 
AUTODOCK VINA (Trott et al. 2010). Carbon atoms of RADH side chains are shown 
in coral; n-pentyl phenyl ketone is presented in ball-and-stick format with the carbon 
atoms in black.  
The model presented in Figure 28 suggests that flexible side chain of n-pentyl 
phenyl ketone can fit in the region of hydrophobic tunnel through contortion in the 
enzyme. Less flexible substituents, such as aromatic rings would not be 
accommodated. This goes in line with substrate specificity studies, which clearly 
demonstrated that compounds such as benzoin or α-pyridoin are poor substrates for 
RADH (see Table 7). 
The 3D structure of RADH provides the structural explanation for the recognition 
of bulky-bulky ketones in a hydrophobic tunnel near the surface of the enzyme. It 
will further be beneficial to identify crucial amino acids in the active site for 
stereoselectivity and for the acceptance of sterically hindered substrates. 
Subsequently, rational engineering or randomised mutagenesis of target residues 
may improve or alter the enzyme’s specificity. 
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3.6 Reaction engineering 
Since the ADHs employed in this work for the further reduction of α-hydroxy 
ketones require NAD(P)H in stoichiometric concentration, there is a necessity to 
develope suitable cofactor regeneration systems (see chapter 1.7), which can be 
conducted either substrate-coupled (see chapter 1.7.1) or enzyme-coupled approach 
(see chapter 1.7.2). Both of these approaches require the application of an 
additionally co-substrate, which is oxidised to the co-product in stoichiometric 
amounts to the product of interest (Figure 29). In order to shift the potential 
reaction equilibrium to the desired product and to avoid unwanted side effects 
caused by the accumulation of the co-product, it is beneficial to remove the co-
product during the course of the reaction.   
 
Figure 29. 2-Step enzymatic synthesis of chiral 1,2-diols combining carboligation and 
oxidoreduction with cofactor regeneration. 
In frame of this work a modified approach of cofactor regeneration was developed, 
where by smart choice of the co-substrate for the cofactor recycling process the 
formed co-product is in situ removed by its reuse as a substrate for the carboligation 
step (Figure 30). 
 
Figure 30. Novel recycling cascade reaction with smart in situ cofactor regeneration and co-product 
recycling. Abbreviations: S = substrate, I = intermediate, P = product, E = enzyme 
(Publication III). 
 
3.6.1 Optimisation of the cofactor regeneration system 
In this work the enzymatic approach of cofactor regeneration (substrate- and 
enzyme-coupled cofactor regeneration) was comparatively tested.  
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3.6.1.1  Substrate-coupled approach 
The substrate-coupled approach of cofactor regeneration is also called “biocatalytic 
hydrogen transfer”. For later implementation in the enzyme cascade two co-
substrates, ethanol and benzyl alcohol, were tested as hydrogen donors for 
bioreductions catalysed by RADH. The co-substrates for cofactor regeneration were 
chosen such that the respective co-product could subsequently be reused in the first 
carboligation step of the synthetic enzyme cascade. This was done to increases 
atom- and therewith process economy and to reduce waste production. 
Lavandera et al. (Lavandera et al. 2008c) showed that implementation of ethanol 
(10 vol%) for cofactor regeneration at pH 7.5 was suitable for the reduction of 
cyclohexyl(phenyl)methanone. It should be noted that these authors applied 
lyophilised cells containing overexpressed RADH for the reduction (Lavandera et 
al. 2008c). In contrast own cofactor regeneration studies were performed with 
purified RADH. 
This study revealed that ethanol (20-5000 mM) is not a good co-substrate for the 
reduction of rac-2-HPP (10 mM) using isolated RADH since conversions of only 
3% could be achieved. This result suggests that one or more further alcohol 
dehydrogenases present in the host Escherichia coli were probably responsible for 
cofactor regeneration using lyophilised crude cell extracts for the reduction of 
cyclohexyl(phenyl)methanone in the work of Lavandera et al. (Lavandera et al. 
2008c). 
Better results were obtained, when benzyl alcohol was employed as a co-substrate 
for cofactor regeneration. Here conversions up to 59% were achieved under not 
optimised conditions. Further optimisation of the enzyme concentration (0.05-
0.30 mg mL–1) yielded conversions up to 98.5% (Publication III). 
 
3.6.1.2  Enzyme-coupled approach 
For the enzyme-coupled approach TBADH from Thermoanaerobacter brockii was 
tested, since this enzyme was already successfully used in lab- and industrial-scale 
(Bastos et al. 1999; Bastos et al. 2002; Röthig et al. 1990).  
Oxidation of ethanol catalysed by TBADH gave more promising initial conversions 
(up to ~10%) than first substrate-coupled trials (up to 3%, see paragraph 3.6.1.1) 
under not optimised conditions. Further optimisation revealed conversions of 71% 
with 2 500 mM ethanol (Publication III). 
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3.6.2  Synthetic cascade reaction 
Synthetic cascade reactions using enzymes have many advantages such as: 
elimination of dangerous and toxic catalysts, atom and energy economy, 
elimination of unnecessary derivatisation and last but not least reduction of waste 
production (see paragraph 1.12, Table 6). These benefits of enzymatic cascade 
reactions go in line with the 12 principles of Green Chemistry and the 
PRODUCTIVELY concept (see paragraph 1.1).  
In this work a new cascade reaction was developed, encompassing carboligation 
and a subsequent reduction step with cofactor regeneration system in one pot 
(Figure 30). Furthermore, one of a key objective was the combination of cheap 
starting materials yielding the desired 1,2-diol with highest possible stereoselectivity 
and maximal conversion. Therefore, two cofactor regeneration systems (substrate- 
and enzyme-coupled approaches) were compared. The cascade was designed such 
that the by-product formed during cofactor regeneration was reused for the 
carboligation step. This approach ensured high atom and step economy. 
 
3.6.2.1  Cascade reaction using substrate-coupled cofactor 
regeneration 
Three different routes for cascade reactions with substrate-coupled cofactor 
regeneration were investigated. They varied on the implemented starting 
compounds at the beginning of the cascade reaction (Figure 31): 
 ROUTE A: where acetaldehyde (150 mM), benzyl alcohol (120 mM), and the 
intermediate (R)-2-HPP (10 mM) were applied for the production of 
respective 1,2-diol; 
 ROUTE B: where benzaldehyde (10 mM), acetaldehyde (150 mM) and 
benzyl alcohol (120 mM) were applied; 
 ROUTE C: where only benzyl alcohol (120 mM) and acetaldehyde (150 mM) 
were used to start the production of the chiral 1,2-diol. Thereby diol 
formation can only occur, if the cofactor regeneration system is effectively 
working, since benzaldehyde for carboligation has to be formed by oxidation 
of benzyl alcohol. 
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Figure 31. Process design for a synthetic cascade reactions using substrate-coupled cofactor 
regeneration. Substrates which are present in the reaction at time t=0 are highlighted in 
red. BAL = Pseudomonas fluorescens benzaldehyde lyase, RADH = Ralstonia sp. alcohol 
dehydrogenase (adapted from Publication III, modified). 
The first cascade reactions with substrate-coupled cofactor-regeneration under non- 
optimised reaction conditions (Table 10, entry 8) showed only low overall 
conversions of 19.7±0.5% and 18.6±0.9% for routes A and B, respectively. Thereby 
route A is a kind of control reaction, which gives an insight into the efficiency of 
the cofactor regeneration system. The overall conversion is defined as the 
conversion all aromatic compounds to the desired product ((1R,2R)-diol) which 
were applied to start the reaction. In case of route C, where only acetaldehyde and 
benzyl alcohol were added to start the reaction, an overall conversion of only 
11.8±0.2% under not optimised conditions was achieved. However, if conversion is 
calculated based on the co-product ≥ 98% of the benzaldehyde produced by 
oxidation of benzyl alcohol was transformed into the product (Table 10, entry 5). 
Optimisation of the pH-value, concentration of NADP+ and RADH increased the 
overall conversion up to 73% (route B, see Table 10, entry 13), when benzyl alcohol 
was applied for the production of benzaldehyde for the carboligation step. Here 
again the co-product was transformed almost completely (97.2%) into the diol 
(Publication III). 
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Table 10. Optimisation of the synthetic cascade reaction with the substrate-coupled approach. 
Depending on the mode of the cascade reaction, different initial concentrations of starting 
materials were applied: route A: acetaldehyde: 150 mM, (R)-2-HPP: 10 mM and benzyl 
alcohol: 120 mM; route B: acetaldehyde: 150 mM, benzaldehyde: 10 mM and benzyl 
alcohol: 120 mM; route C: acetaldehyde: 150 mM and benzyl alcohol: 120 mM; convoverall 
– overall conversion is defined as a conversion of all aromatic compounds (benzyl alcohol 
and benzaldehyde with (R)-2-HPP depending on the route) to the 1-phenylpropane-1,2-
diol; convBA – co-product conversion is defined as a conversion of benzaldehyde formed 
during oxidation of benzyl alcohol (Publication III). 
Entry 
Optimised 
parameter 
Route 
    convoverall      convBA Distribution of stereoisomers [%] 
     [%]      [%] (1R,2R) : (1S,2R) : (1R,2S) : (1S,2S) 
 NADP+ [mM] 
1 0.2 A 
B 
C 
27.2±2.2 
21.5±0.2 
9.2±0.2 
99.4±0.2 
99.1±0.1 
98.2±0.2 
98 
98 
> 99 
2 
2 
0 
0 
0 
0 
0 
0 
0 
2 0.4 A 
B 
C 
29.1±1.2 
26.8±1.6 
9.5±0.0 
98.7±0.7 
94.2±6.7 
98.5±0.3 
97 
97 
> 99 
3 
3 
0 
0 
0 
0 
0 
0 
0 
3 0.6 A 
B 
C 
32.2±0.4 
23.4±1.0 
9.7±0.1 
98.5±1.0 
99.0±0.0 
98.0±0.3 
97 
98 
> 99 
3 
2 
0 
0 
0 
0 
0 
0 
0 
4 0.8 A 
B 
C 
31.4±1.8 
27.7±1.8 
9.8±0.0 
98.7±0.7 
98.4±1.0 
98.5±0.4 
97 
97 
> 99 
3 
3 
0 
0 
0 
0 
0 
0 
0 
 pH-value 
5 8.0 A 
B 
C 
19.7±0.5 
18.6±0.9 
11.8±0.2 
99.1±0.5 
99.1±0.4 
98.6±0.4 
98 
98 
> 99 
2 
2 
0 
0 
0 
0 
0 
0 
0 
6 8.5 A 
B 
C 
22.8±1.4 
26.5±3.5 
15.9±0.3 
99.2±0.2 
98.8±0.0 
99.2±0.6 
98 
98 
> 99 
2 
2 
0 
0 
0 
0 
0 
0 
0 
7 9.0 A 
B 
C 
25.1±3.2 
24.3±2.9 
15.3±0.2 
99.2±0.0 
99.1±0.1 
98.5±0.6 
98 
99 
> 99 
2 
1 
0 
0 
0 
0 
0 
0 
0 
 RADH concentration [mg mL–1] 
8 0.10 A 
B 
C 
19.7±0.5 
18.6±0.9 
11.8±0.2 
99.1±0.5 
99.1±0.4 
98.6±0.4 
98 
98 
> 99 
2 
2 
0 
0 
0 
0 
0 
0 
0 
9 0.24 A 
B 
C 
27.2±1.3 
32.6±0.3 
29.5±1.3 
99.1±0.1 
98.8±0.5 
98.5±0.6 
99 
99 
99 
1 
1 
1 
0 
0 
0 
0 
0 
0 
10 0.33 A 
B 
C 
42.7±3.7 
44.6±1.4 
36.1±3.6 
98.6±0.7 
98.0±0.5 
97.9±0.1 
98 
98 
99 
2 
2 
1 
0 
0 
1 
0 
0 
0 
11 0.65 A 
B 
C 
56.5±1.0 
54.9±3.7 
48.8±5.8 
98.5±0.3 
98.1±0.6 
98.1±0.1 
95 
95 
95 
3 
3 
3 
2 
2 
2 
0 
0 
0 
12 2.00 A 
B 
C 
68.3±3.0 
67.6±4.5 
68.0±2.1 
98.6±0.1 
98.2±0.3 
98.6±0.5 
97 
96 
96 
2 
3 
2 
1 
1 
2 
0 
0 
0 
13 3.75 B 73.4 97.2 90 8 2 0 
Full conversion of the synthetic cascade reaction with substrate-coupled cofactor 
regeneration cannot be achieved, since benzyl alcohol always has to be present in a 
defined concentration for the oxidation reaction in order to enable cofactor 
regeneration. In the presence of high RADH concentrations (up to 3.75 mg mL–1) 
conversion of benzyl alcohol reached a maximum of 89.8% (t=0 h: cbenzyl alcohol: 
127 mM, t=45 h: cbenzyl alcohol: 13 mM). Conversion is strongly restricted by the 
benzyl alcohol concentration in the batch reaction. The KM-value for the RADH-
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catalysed oxidation of benzyl alcohol (at pH 9.0) was determined to be 
12.3±2.7 mM (Publication II). When the concentration of benzyl alcohol in the 
reaction vessel dropped below a concentration of ca. 230 mM (Vmax) the enzyme 
catalyses the oxidation of benzyl alcohol no longer with maximal activity. This is 
the reason, why the co-substrate has to be applied in excess. 
This conclusively also means that the calculation of conversion to the desired 1,2-
diol should be based on the amount of converted benzaldehyde (resulting from 
direct implementation of benzaldehyde and/or oxidation of benzyl alcohol to 
benzaldehyde) and not based on the sum of all aromatic substrates and products 
apparent in the vessel.  
Further, the application of higher amounts of benzyl alcohol is limited by its 
solubility in aqueous media, which is ~47 g L–1 (~435 mM, at pH 9, 25 °C) (O’Neil 
2006), albeit its additional organic compounds in buffer system will decrease the 
solubility further. It was observed that solubility problems occurred already with 
250 mM benzyl alcohol, in the cascade reaction, leading in the formation of 
emulsions (visual observation). In the presence of very high enzyme concentrations 
(≥ 0.33 mg mL–1), a drop of stereoselectivity of the catalysed reaction was observed. 
When the overall conversion of the cascade reaction was exceeding > 40%, two 
another stereoisomers (1S,2R) and (1R,2S)) of 1-phenylpropane-1,2-diol were 
formed. When 3.75 mg mL–1 RADH was implemented, the following stereoisomers 
were detected: (1R,2R): 90.4%, (1S,2R): 7.8% and (1R,2S): 1.8%.  The formation of 
the (1S,2R)-diol can be explained by an non-perfect stereoselectivity of RADH. 
Under the conditions tested the high concentration of the enzyme obviously results 
also in the (S)-selective reduction of (R)-2-HPP to a certain extend. The presence of 
the (1R,2S)-diol (1.8%) can most probably be explained by keto-enol tautomerism 
of the 1,2-diol at pH 9. The fourth possible stereoisomer, the (1S,2S)-diol, could not 
be detected in the course of the reaction.  
One solution for the stereoselective production of only one stereoisomer of the  
1,2-diol with substrate-coupled cofactor regeneration in the cascade reaction could 
be a fed-batch process, where benzyl alcohol is continuously fed enabling a constant 
concentration of benzyl alcohol during the reaction. Moreover, an appropriate 
enzyme concentration should be applied in order to produce only one stereoisomer 
of the desired product and to avoid the side reaction of “stereoinversion” or use of a 
2-phase reaction system should be tried, since in organic solvent (methyl tert-butyl 
ether, MTBE) no formation of the other unwanted stereoisomers of the 1,2-diol 
were observed (discussion with Jochen Wachtmeister).   
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3.6.2.2  Cascade reaction using enzyme-coupled cofactor regeneration 
As described for the substrate-coupled cofactor regenerations synthetic cascade 
reaction employing enzyme-coupled cofactor regeneration were conducted in three 
routes (Figure 32): 
 ROUTE A: where, similarly to the cascade approach mentioned above, two 
substrates, benzaldehyde (10 mM) and ethanol (2500 mM), and the 
intermediate (R)-2-HPP (10 mM) were applied for the production of 
respective 1,2-diol; 
 ROUTE B: where benzaldehyde (10 mM), acetaldehyde (100 mM), and 
ethanol (2500 mM) were applied; 
 ROUTE C: where only two substrates, benzaldehyde (10 mM) and ethanol 
(2500 mM), were used for the production of chiral 1,2-diol. Thereby diol 
formation can only occur, if the cofactor regeneration system is working, 
since acetaldehyde for the carboligation step has to be formed by oxidation 
of ethanol.  
 
Figure 32. Process strategies for a synthetic cascade reaction using enzyme-coupled cofactor 
regeneration. Substrates which are present in the reaction at time t=0 are highlighted in 
red.  BAL = Pseudomonas fluorescens benzaldehyde lyase, RADH = Ralstonia sp. alcohol 
dehydrogenase, TBADH = Thermoanaerobacter brockii alcohol dehydrogenase (adapted 
from Publication III, modified).  
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Synthetic cascade reactions using the enzyme-coupled approach for cofactor 
regeneration revealed very good overall conversions. Best overall conversions were 
obtained for route B, where 95% conversion was determined. Very good 
conversions were also obtained for route A (78%) and route C (69%). In all tested 
routes only the (1R,2R)-diol (Figure 20) was obtained (de > 99%). 
 
3.6.2.3  Comparison of cascade reactions using the substrate- and 
enzyme coupled approach 
As demonstrated above the studied synthetic cascade reactions with two types of 
cofactor regeneration systems showed differences in the overall conversions. 
Conclusively it depends very much on the set-up of the cascade, which regeneration 
system is to be favoured. In terms of economic efficiency, implementation of a third 
enzyme for the cascade should be circumvented, if possible, since enzyme costs 
(especially of purified enzymes) are one major cost factor of the reaction. However, 
if highest possible stereoselectivities are most important, the enzyme-coupled 
cofactor regeneration is the favoured mode for the studied reaction. 
 
3.6.2.4  Further cascade reactions 
Apart from the described reactions system, a synthetic enzyme cascaded using BFD 
from Pseudomonas putida in combination with the alcohol dehydrogenase from 
Ralstonia sp. (RADH) was additionally studied. In contrast to BAL, BFD catalyses 
the carboligation of benzaldehyde and acetaldehyde yielding (S)-2-HPP. 
Subsequent reduction by RADH should give access to the respective (1R,2S)-diol. 
Preliminary results gave overall conversions of 13.5%. Nevertheless, similar initial 
results were obtained for the non-optimised reaction employing BAL and RADH. 
As was demonstrated in chapter 3.6.2.1 reaction engineering and mathematical 
modelling increased conversion (up to 73.4%). Therefore the BFD-RADH enzyme 
combination seems to be a good starting point for a future optimisation to obtain 
the (1R,2S)-diol. 
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IV   Conclusion and future 
perspectives 
 
In this thesis the high potential of biocatalysis for the stereoselective synthesis of 
chiral vicinal diols was demonstrated.  
Reduction of various α-hydroxy ketones allowed the setup of a platform of diversely 
substituted and stereocomplementary vicinal diols. Investigation of the substrate 
scope of eight different alcohol dehydrogenases gave insight into the potential of α-
hydroxy ketones reduction catalysed by oxidoreducteases and resulted in the 
investigation of one outstanding catalyst, the alcohol dehydrogenase from Ralstonia 
sp. (RADH).  
Isolated for the first time and biochemically characterised, RADH confirmed its 
extremely high potential for bulky compounds, and its surprisingly high affinity for 
the reduction of α-hydroxy ketones compared to aldehydes was confirmed by 
kinetic studies.  
In collaboration with the University of York, crystallisation of RADH was 
performed in order to elucidate the enzyme structure and to understand its high 
preference for bulky substrates. The solved structure gives insight into the 
architecture of the enzymes active centre. It further opens the way for protein 
engineering in a rational manner in order to expand the substrate range of the 
enzyme for the reduction of e.g. benzoin-derivatives.  
Moreover, synthetic enzyme cascade reactions for the stereoselective production of 
(1R,2R)-diols could be established, where atom- and step economy could be 
increased by implementation of an enzymatic cofactor regeneration system with  
smart in situ by-product recycling. Thus, by reaction engineering and modelling 
studies, optimised synthetic cascade reactions produced vicinal diols more 
sustainable than described so far. Due to the improvement, atom economy could be 
increased, waste production reduced and thus overall process economy increased.   
The presented work was performed either by implementation of crude cell extracts 
containing overexpressed alcohol dehydrogenases or by the usage of purified 
enzyme in order to exclude potent side reactions. In order to make the process for 
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the production of chiral diols faster and therewith more efficient, investigation of 
catalyst implementation in form of whole cells are ongoing in a follow-up project. 
This would circumvent costs and time spending enzymes purification. Furthermore, 
increase of substrate load for the biotransformations by implementation of neat 
substrates or addition of organic co-solvents can increase space-time yields of the 
synthetic cascade reaction, if a system can be established, under which all enzymes 
are still active even under non-conventional reaction conditions. 
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5.1. DNA sequence of RADH (without His-tag) 
  1 ATGTATCGTC TGCTGAATAA AACCGCAGTT ATTACCGGTG GTAATAGCGG TATTGGTCTG 
       61 GCAACCGCAA AACGTTTTGT TGCCGAAGGT GCCTATGTTT TTATTGTTGG TCGTCGTCGT 
      121 AAAGAACTGG AACAGGCAGC AGCAGAAATT GGTCGTAATG TTACCGCAGT TAAAGCCGAT 
      181 GTTACCAAAC TGGAAGATCT GGATCGTCTG TATGCAATTG TTCGTGAACA GCGTGGTAGC 
      241 ATTGATGTTC TGTTTGCAAA TAGCGGTGCC ATTGAACAGA AAACCCTGGA AGAAATTACA 
      301 CCGGAACATT ATGATCGCAC CTTTGATGTT AATGTGCGTG GTCTGATTTT TACCGTTCAG 
      361 AAAGCACTGC CGCTGCTGCG TGATGGTGGT AGCGTTATTC TGACCAGCAG CGTTGCCGGT 
      421 GTTCTGGGTC TGCAGGCACA TGATACCTAT AGCGCAGCAA AAGCAGCAGT TCGTAGCCTG 
      481 GCACGTACCT GGACCACCGA ACTGAAAGGT CGTAGCATTC GTGTTAATGC AGTTAGTCCG 
      541 GGTGCAATTG ATACCCCGAT TATTGAAAAT CAGGTTAGCA CCCAGGAAGA AGCAGACGAA 
      601 CTGCGCGCAA AATTTGCAGC AGCAACACCG CTGGGTCGTG TTGGTCGTCC GGAAGAACTG 
      661 GCAGCAGCCG TTCTGTTTCT GGCAAGTGAT GATAGCAGCT ATGTTGCAGG TATTGAACTG 
      721 TTTGTTGATG GTGGTCTGAC CCAGGTTTAA 
 
ATG – start codon 
TAA – stop codon 
 
 
5.2. Protein sequence of RADH (without His-tag) 
        1 MYRLLNKTAV ITGGNSGIGL ATAKRFVAEG AYVFIVGRRR KELEQAAAEI GRNVTAVKAD 
       61 VTKLEDLDRL YAIVREQRGS IDVLFANSGA IEQKTLEEIT PEHYDRTFDV NVRGLIFTVQ 
      121 KALPLLRDGG SVILTSSVAG VLGLQAHDTY SAAKAAVRSL ARTWTTELKG RSIRVNAVSP 
      181 GAIDTPIIEN QVSTQEEADE LRAKFAAATP LGRVGRPEEL AAAVLFLASD DSSYVAGIEL 
      241 FVDGGLTQV– 
 
M – methionine 
“–”– stop codon 
pET-22b_RADH
6120 bps
XhoI
NdeI
ori
RADH
lacI
AmpR
f1 origin
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5.3. Primers for RADH subcloning 
RADH_FOR:  
C CAG GGA CCA GCA ATG TAT CGT CTG CTG AAT AAA ACC GCA GTT ATT ACC G 
RADH_REV: 
 GA GGA GAA GGC GCG TTA TTA AAC CTG GGT CAG ACC ACC ATC AAC AAA CAG 
Bolded: standard LIC3C sequences 
ATG – start codon 
TAA – stop codons 
not bolded: sequence of RADH 
Universal LIC3C sequences for LIC-cloning: 
3C FOR:  CCA GGG ACC AGC A    (LIC3C forward primer addition) 
REV:   GAG GAG AAG GCG CGT TTA      (Universal reverse primer addition) 
TTA – stop codon  
 
5.4. DNA sequence of His-RADH 
1 ATGGGCAGCA GCCATCATCA TCATCATCAC AGCAGCGGCC TGGAAGTTCT GTTCCAGGGA 
       61 CCAGCAATGT ATCGTCTGCT GAATAAAACC GCAGTTATTA CCGGTGGTAA TAGCGGTATT 
      121 GGTCTGGCAA CCGCAAAACG TTTTGTTGCC GAAGGTGCCT ATGTTTTTAT TGTTGGTCGT 
      181 CGTCGTAAAG AACTGGAACA GGCAGCAGCA GAAATTGGTC GTAATGTTAC CGCAGTTAAA 
      241 GCCGATGTTA CCAAACTGGA AGATCTGGAT CGTCTGTATG CAATTGTTCG TGAACAGCGT 
      301 GGTAGCATTG ATGTTCTGTT TGCAAATAGC GGTGCCATTG AACAGAAAAC CCTGGAAGAA 
      361 ATTACACCGG AACATTATGA TCGCACCTTT GATGTTAATG TGCGTGGTCT GATTTTTACC 
      421 GTTCAGAAAG CACTGCCGCT GCTGCGTGAT GGTGGTAGCG TTATTCTGAC CAGCAGCGTT 
      481 GCCGGTGTTC TGGGTCTGCA GGCACATGAT ACCTATAGCG CAGCAAAAGC AGCAGTTCGT 
      541 AGCCTGGCAC GTACCTGGAC CACCGAACTG AAAGGTCGTA GCATTCGTGT TAATGCAGTT 
      601 AGTCCGGGTG CAATTGATAC CCCGATTATT GAAAATCAGG TTAGCACCCA GGAAGAAGCA 
      661 GACGAACTGC GCGCAAAATT TGCAGCAGCA ACACCGCTGG GTCGTGTTGG TCGTCCGGAA 
      721 GAACTGGCAG CAGCCGTTCT GTTTCTGGCA AGTGATGATA GCAGCTATGT TGCAGGTATT 
      781 GAACTGTTTG TTGATGGTGG TCTGACCCAG GTTTAA 
 
5.5. Protein sequence of His-RADH 
1 MGSSHHHHHH SSGLEVLFQG PAMYRLLNKT AVITGGNSGI GLATAKRFVA EGAYVFIVGR 
       61 RRKELEQAAA EIGRNVTAVK ADVTKLEDLD RLYAIVREQR GSIDVLFANS GAIEQKTLEE 
      121 ITPEHYDRTF DVNVRGLIFT VQKALPLLRD GGSVILTSSV AGVLGLQAHD TYSAAKAAVR 
      181 SLARTWTTEL KGRSIRVNAV SPGAIDTPII ENQVSTQEEA DELRAKFAAA TPLGRVGRPE 
      241 ELAAAVLFLA SDDSSYVAGI ELFVDGGLTQ V- 
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MGSSHHHHHH SSGLEVLFQG PA   – introduced additional amino acids 
LEVLFQ/G P      – sequence recognition motif for HRV 3C 
protease cleavage 
Underlined     – His6-tag 
GPA      – amino acids remained after HRV 3C protease  
cleavage 
 
5.6. Protein sequence of His-RADH: after His-tag cleavage 
1 GPAMYRLLNK TAVITGGNSG IGLATAKRFV AEGAYVFIVG RRRKELEQAA AEIGRNVTAV 
       61 KADVTKLEDL DRLYAIVREQ RGSIDVLFAN SGAIEQKTLE EITPEHYDRT FDVNVRGLIF 
      121 TVQKALPLLR DGGSVILTSS VAGVLGLQAH DTYSAAKAAV RSLARTWTTE LKGRSIRVNA 
      181 VSPGAIDTPI IENQVSTQEE ADELRAKFAA ATPLGRVGRP EELAAAVLFL ASDDSSYVAG            
      241 IELFVDGGLT QV- 
 
 
5.7. General procedure for subcloning 
Component 
Volume [µL] 
Control #1 #2 #3 
FOR_Primer 1.0 1.0 1.0 1.0 
REV_Primer 1.0 1.0 1.0 1.0 
dNTP’s 5.0 5.0 5.0 5.0 
KOD Hot Start Polymerase 1.0 1.0 1.0 1.0 
MgSO4 (25 mM) 2.0 2.0 2.0 2.0 
Buffer (10X) 5.0 5.0 5.0 5.0 
Template DNA (50 ng µL–1) – 0.5 0.5 0.5 
DMSO – – 1.0 2.0 
Water 35.0 34.5 33.5 32.5 
Total volume [µL] 50 50 50 50 
pET-28a_His-RADH
6145 bps
NdeI
NcoI
ori
His-RADH
lacI
KanR
f1 origin
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5.8. Thermocycler program for LIC-cloning 
 Step Temperature [°C] Time N° cycles 
Initial denature 94 2 min 1 
Denature 94 30 sec 35 
Anneal 50 30 sec  
Extension 72 30 sec  
Final extension 72 3 min 1 
Hold 4 n 1 
 
5.9. Protocol for His-RADH purification using IMAC 
Purification of His-RADH proceeds in three chromatographic steps encompassing 
immobilised metal affinity chromatography, desalting and gel filtration.  
1. STEP: Immobilised metal affinity chromatography (IMAC) using HiTrap 
Chelating HP column (bed volume: 5 mL, Amersham Biosciences). The 
fusion protein was purified as follows: 
a. WASH I: 10 column volumes (50 mL total wash step) with buffer A, 
flow rate: 2 mL min–1 
b. WASH II: 10 column volumes (50 mL total wash step) with buffer B, 
flow rate: 2 mL min–1 
c. ELUTION: 20 column volumes, gradient (0-100% buffer C) (100 mL 
total elution step) and next ~10-20 column volumes with buffer C, 
flow rate: 1 mL min–1 
2. STEP: Desalting using gel filtration, HiPrep 26/10 Desalting column (bed 
volume: 53 mL, Amersham Biosciences). To this purpose buffer D was 
applied. Onto column 10-15 mL of purified protein was loaded. Desalting 
procedure was carried out with flow rate of 5 mL min–1. Fractions 
containing the enzyme of interest were next concentrated using 
ultrafiltration membrane (VIVASPIN 20, cut-off: 30 000 Da, MWCO 30) 
and are a subject of the last purification step.  
3. STEP: Gel filtration using Superdex HiLoad 75/16 PrepGrade (bed volume: 
120 mL, Amersham Biosciences). Collected and concentrated (up to 2 mL) 
sample was loaded onto the column and purification proceeded under flow 
rate of 0.5-1.0 mL min–1. Fractions containing purified enzyme were 
concentrated as described above 
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Description Component Concentration [mM] 
Buffer A  
(resuspension and wash I) 
TRIS 
NaCl 
CaCl2 
Imidazole 
Glycerol 
50 
500 
1.0 
20 
10 vol%  
Buffer B  
(wash II) 
TRIS 
NaCl 
CaCl2 
Imidazole 
Glycerol 
50 
500 
1.0 
50 
10 vol%  
Buffer C  
(elution) 
TRIS 
NaCl 
CaCl2 
Imidazole 
Glycerol 
50 
500 
1.0 
300 
10 vol%  
Buffer D  
(desalting and gel filtration) 
TRIS 
NaCl 
CaCl2 
50 
150 
1.0 
 
5.10. DNA sequence of strep-SADH 
                   1 ATGACCACCC TGCCGACCGT TCTGATTACC GGTGCAAGCA GCGGTATTGG TGCAACCTAT 
       61 GCAGAACGTT TTGCACGTCG TGGTCATGAT CTGGTTCTGG TTGCACGTGA TAAAGTTCGT 
      121 CTGGATGCAC TGGCAGCACG TCTGCGTGAT GAAAGCGGTG TTGCAGTTGA AGCACTGCAG 
      181 GCAGATCTGA CCCGTCCGGC AGATCTGGCA GCAGTTGAAA TTCGTCTGCG TGAAGATGCA 
      241 CGTATTGGCA TTCTGATTAA TAATGCAGGT ATGGCACAGA GCGGTGGTTT TGTTCAGCAG 
      301 ACCGCAGAAG GTATTGAACG TCTGATTACC CTGAATACCA CCGCACTGAC CCGTCTGGCT 
      361 GCAGCAGTTG CACCGCGTTT TGTTCAGAGC GGCACCGGTG CAATTGTTAA TATTGGTAGC 
      421 GTTGTTGGTT TTGCACCGGA ATTTGGTATG AGCATTTATG GTGCAACCAA AGCCTTTGTT 
      481 CTGTTTCTGA GCCAGGGTCT GAATCTGGAA CTGAGCCCGA GCGGTATTTA TGTTCAGGCA 
      541 GTTCTGCCTG CAGCAACCCG TACCGAAATT TGGGGTCGTG CAGGTATTGA TGTTAATACC 
      601 CTGCCGGAAG TTATGGAAGT TGATGAACTG GTTGATGCAG CACTGGTTGG TTTTGATCGT 
      661 CGTGAACTGG TTACCATTCC TCCGCTGCAT GTTGCAGCAC GTTGGGATGC ACTGGATGGT 
      721 GCACGTCAGG GTCTGATGAG CGATATTCGT CAGGCACAGG CAGCAGATCG TTATCGTCCG 
      781 GAAGCAAGCG CATGGTCACA TCCGCAGTTT GAAAAATAA 
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5.11. Protein sequence of strep-SADH 
        1 MTTLPTVLIT GASSGIGATY AERFARRGHD LVLVARDKVR LDALAARLRD ESGVAVEALQ 
       61 ADLTRPADLA AVEIRLREDA RIGILINNAG MAQSGGFVQQ TAEGIERLIT LNTTALTRLA 
      121 AAVAPRFVQS GTGAIVNIGS VVGFAPEFGM SIYGATKAFV LFLSQGLNLE LSPSGIYVQA 
      181 VLPAATRTEI WGRAGIDVNT LPEVMEVDEL VDAALVGFDR RELVTIPPLH VAARWDALDG 
      241 ARQGLMSDIR QAQAADRYRP EASAWSHPQF EK- 
WSHPQF EK – strep-tag sequence 
 
pET-22b_SADH
6189 bps
XhoI
NdeI
ori
SADH
lacI
AmpR
f1 origin
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